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Batten disease, or NCL (neuronal ceroid lipofuscinosis), is a collection of 13 
pathologically similar, genetically distinct, autosomal recessive, neurodegenerative 
lysosomal storage diseases. Primarily affecting children between the ages of 5 and 8, 
NCLs have an incidence of 1 in 12,500 live births and are all currently incurable and 
fatal. While each of the 13 forms of NCLs are genetically different, they all result in 
severe cortical atrophy and therefore display similar symptoms of visual impairment, 
seizures, behavioural and personality changes, regression in communication and 
motor skills and dementia, ultimately resulting in premature death in the patient’s 
teens to early 20s. Another common trait of the diseases is the accumulation of 
autofluorescent storage materials in cell lysosomes. The association between the 
accumulation of lysosomal storage materials and neurodegeneration is unknown, 
however several methods have been suggested including inflammation and apoptosis. 
Current treatments are only symptom based.  
 
Cannibidiol (CBD) is one of two main cannabinoids found in cannabis. The 
compound has been shown to have both antiepileptic and anti-inflammatory, 
neuroprotective properties. Unlike its other main counterpart, delta-9-
tetrahydrocannabinol (Δ9-THC), CBD does not have psychoactive activity, which is 
known to interfere with neuronal development. These properties are desirable in the 
treatment of a childhood neurodegenerative disease.  
 
In this investigation, CBD was administered orally to Cln6nclf mice, a naturally 
occurring murine model of one form of the disease, CLN6 for a period of 4 weeks. 
Behavioural assessments and immunohistochemical analysis of the left thalamus, 
hippocampus and motor cortex of the animals was performed. Thirty-three male and 
female affected and unaffected animals were given daily doses of either 10 mg/kg 
CBD, 25 mg/kg CBD or vehicle only via voluntary oral dosing using raspberry jelly. 
On the second to last day of treatment, each animal performed a marble burying test 
followed by an elevated plus maze test. Following euthanasia and perfusion, the left 
hemispheres were collected and sectioned into 50 µm slices and stained and imaged 
for inflammatory markers glial fibrillary acidic protein (GFAP), cluster of 
differentiation 68 (CD68) and neuronal nitric oxide synthase (nNOS), as well as the 
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angiogenesis marker doublecortin (DCX). Sections were also imaged for 
quantification of the autofluorescent material.  
 
The behavioural assessments yielded no meaningful difference between any of the 
treatment groups. Immunohistochemical staining and autofluorescent imaging 
quantification showed that while differences were detected between the affected and 
unaffected control animals, the treated animals did not show a significant difference 
from the affected control group. These results do however suggest that with prolonged 
treatment may yield more meaningful results. Furthermore, the weights of the animals 
stayed within a healthy range throughout the treatment period. The use of the sweet 
jelly did not enable the mice to gain weight while providing an easy, safe, convenient 
and tasty method of drug administration. This provides further evidence for the 
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Chapter One: Introduction  
Batten disease is a collection of genetic neurodegenerative disorders with variable 
physical presentations and causative factors; however, all end in premature death of 
patients. Collectively there are no treatments to rectify the diseases and available 
treatments are generally palliative. There are many methods of curative treatment 
being explored from dietary supplements to gene therapy to amend disease pathology. 
Included in this is the treatment with one of the main constituents of the cannabis 
plant, cannabidiol (CBD). The cannabinoid has shown beneficial properties for the 
treatment of Batten patients both symptomatically and corrective.  
 
1.1 Neuronal Ceroid Lipofuscinosis  
Neuronal ceroid lipofuscinosis (NCL, commonly referred to as Batten Disease) is the 
general name for a collection of genetically distinct autosomal recessive 
neurodegenerative lysosomal storage diseases (LSD). NCLs generally affect children 
between the ages of 5 and 8 years old. Collectively the disorders are rare, with an 
occurrence of approximately one in 12,500 live births, although rates vary 
geographically (Rider & Rider; 1988, Haltia, 2006). The disorders are likely the most 
common neurogenetic storage diseases in children and are always fatal. Most patients 
living till their late teens to early 20’s, with only a minority living to their early 30’s 
(Rider & Rider, 1988).  
 
Initial symptoms include the progressive deterioration of vision and motor skills and 
changes in mood and behaviour. This is followed by myoclonic epileptic seizures, at 
which point the disease is usually diagnosed. Further deterioration renders the 
children bed-ridden where they experience continued cortical atrophy before 
succumbing to the illness (Santavuori, et al., 2000; Jalanko & Braulke, 2009; Warrie, 
et al., 2013). There is currently no cure, and treatment is symptom based. 
 
Much about the disease remains unknown, particularly regarding protein functions 
and methods of effective treatments both corrective and symptomatic.  Paired with the 
mortiferous nature of the disease, this highlights the critical importance of research in 
this growing field. The use of effective animal models for several forms of NCL has 
been an invaluable resource in Batten disease research (Bronson, et al., 1998, Jolly, et 
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al., 1980; Morgan et al., 2013) and provide a great deal of optimism for not only 
researchers, but more importantly the sufferers and the families of the children 
affected by the merciless disease.  
 
1.2 History of NCLs and Nomenclature 
The earliest medical description of any form of NCL, was most likely that of German 
physician Otto Christian Stengel (1795-1890). He reported a juvenile-onset disorder 
(roughly the age of 6 years old) affecting 4 children within the same family. The 
previously normal, healthy children reportedly suffered from gradual deterioration of 
vision, a decline in intellect, seizures and mania. All of the children inevitably 
perished in their early 20s (Stengel, 1826, Trans., 1982). A similar disorder was then 
reported again in 1903 by an English neurologist and pediatrician Fredrick Eustance 
Batten (1865-1918), where “a familial cerebromacular degeneration” was described in 
two sisters (Batten, 1903). And again, two years later, Walter Spielmeyer (1879-1935) 
and Heinrich Vogt (1875-1936) of Germany documented yet another case of what 
was then formally named ‘Batten-Spielmeyer-Vogt disease’, known today as Juvenile 
NCL (JNCL) or CLN3 (Spielmeyer, 1905; Vogt, 1905).  
 
A short time later, an analogous disorder with an earlier onset was described by Jan 
Jansky and Max Bielschowsky (Jansky, 1908, Bielschowsky, 1913). At this time, the 
disease was named Jansky-Bielschowsky disease, now known as late-infantile NCL 
(LINCL) or CLN2. This was then followed by the identification of the rare adult onset 
NCL (ANCL, CLN4) or Kufs disease by Hugo Kufs. Four incidences of the disease 
were described where complementary pathologies to both juvenile NCL and late-
infantile NCL were observed, without the loss of vision (Kufs, 1925). A fourth form 
of the disease was first described in 1973 by Matti Haltia and Pirkko Santavuori when 
investigating a child for suspected GM1 gangliosidosis type II. Formally named 
Haltia-Santavuori disease, now commonly known as classic infantile NCL (INCL) or 
CLN1 (Haltia et al., 1973a; Haltia, et al., 1973b; Santavuori et al., 1973).  
 
Additional variants of the disease have been identified and have been subsequently 
named after their geographical location of discovery. Finnish variant late infantile, 
also described by Santavuori (Santavuori, et al., 1982), which is also known as late-
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infantile variant (vLINCL) or CLN5. Indian variant, or early-juvenile/late infantile 
(vLINCL, CLN6) was described by Lake and Cavanagh in 1978 (Lake & Cavanagh, 
1978), followed by Turkish variant late infantile or CLN7 in 1999 (Wheeler et al., 
1999). Finally, Northern epilepsy/EPMR late infantile variant also know as CLN8 
was identified as a NCL in 1994 (Hirvashiemi et al., 1994). 
 
1.3 Types of NCL 
Lysosomal storage diseases (LSD) are, by definition, diseases in which lysosome 
activity is in some way impeded leading to the accumulation of storage material. 
While the content of accumulated materials may differ in the over 50 unique genetic 
LSDs characterised to date, they all come under the umbrella term of LSDs. Although 
in some cases the causative genetic mutations may have been identified, the exact 
reason for the accumulation or the exact function of the mutated proteins remains 
unclear in NCLs (Getty & Pearce, 2011).  
 
Despite possessing diverse underlying biological aetiologies, ages of onset, severity 
and morphology, NCLs are grouped together based on the common 
pathophysiological feature of neuronal accumulation of autofluorescent pigments in 
the central nervous system (CNS) and peripheral lysosomes (Nita, et al., 2016; 
Jalanko & Braulk, 2009). Currently 13 genetically different forms of the disease have 
been identified. Some of which, such as infantile NCL (CLN1) and late-infantile NCL 
(CLN2) are somewhat well established and better understood (Vesa, et al., 1995; 
Rawlings & Barrett, 1999). Other, more recent discoveries, such as CLN9, are less 
understood but are found to be phenotypically and genetically different from 
previously established forms (Haltia, 2003). The general information about all known 
forms of NCL and their causative genes known to date is outlined in Table 1. 
 
As aforementioned, many of the functions of the affected proteins are unknown. This 
is the case for all NCLs with the exception of soluble proteins palmitoyl protein 
thioesterase 1 (PPT1, implicated in CLN1), tripeptidyl peptidase 1 (TTP1, implicated 
in CLN2), and Cathepsin D (CTSD, implicated in CLN10). Varying forms of 
mutations to the PPT1 gene result in varying forms of PPT1 dysfunction (Vesa, et al., 
1995; Greaves & Chamberlain, 2007). These mutations, which account for protein 
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misfolding, can lead to differential severity and age of onset of infantile NCL, 
dependent on the residual enzyme activity (Das, et al., 2001; Kälviäinen, et al., 2007). 
Although onset is more often than not within the first years of the child’s life (Veas, et 
al., 1995), some cases are not apparent until adulthood (Ramadan, et al., 2007; van 
Diggelen, et al., 2001). While it is not absolutely understood, the function of PTT1 is 
to remove palmitate residues from proteins. Its lack of this activity results in the 
accumulation of mainly saposins A and D (Vesa, et al., 1995; Mitchison, et al., 1998). 
This was shown by its ability to deapalmitoylate hRas in vitro (Hofmann, et al., 
2002). The critical role of this enzyme function however, is not known in lysosomal 
degradation. TPP1, whose dysfunction is responsible for late infantile NCL (CLN2), 
also has a known general function (Rawlings & Barrett, 1999; Sleat, et al., 1997). The 
TPP1 gene has over 100 known mutations, which lead to misfolding and consequently 
impaired enzyme function (Mole, et al., 2005). As a member of the serine carboxyl 
proteinase family, TPP1 is responsible for removing tripeptides from the N-terminus 
of small peptides, with some weak endoproteolytic activity (Ezaki, et al., 2000). 
While the in vivo substrates ofTPP1 are not known, it has been shown in vitro that 
subunit c of mitochondrial ATP synthase may be processed by the enzyme, so 
subsequently may be the reason for the accumulated storage bodies mostly being 
comprised of subunit c (Ezaki, et al., 1999). There are also lower levels of saposins A 
and D in TPP1 mutant cells (Lake & Hall, 1993; Jalanko & Braulke, 2009). The ages 
of onset is around they age of 3 years old, however there have been reports of delayed 
onset till 8 years, where the progression of the disease is also slowed (Slate, et al., 
1999). The final NCL causing protein with known function is CTSD, which is 
implicated in congenital NCL, CLN10 (Zaidi, et al., 2008; Benes, et al., 2008). The 
congenital form of the disease has an extremely rapid progression and infants die at or 
before birth (Siintola, et al., 2006; Ramirez-Monealegre, et al., 2006). The lysosomal 
asparatyl endopeptidase enzyme, which is relevant in neuronal stability (Siintola, et 
al., 2006; Steinfeld, et al., 2006), has been identified to have 7 different mutations 
involved in the disease. Two of these mutations observed in a patient accounted for 
defective posttranslational processing and targeting to the lysosome in addition to 




Table 1.1. General information of the human forms of NCL. *BTB/POZ = BR-C, ttk and bab/pox virus and zinc finger (Vesa, et al., 1995; 
Greaves & Chamberlain, 2007; Bellizzi, et al., 2000; Sleat, et al., 1996; Mole, et al., 2005; Rawlings & Barrett, 1999; Sleat, et al., 1997; 
Steinfeild, et al., 2006; Isosomppi, et al., 2002; Nosková, et al., 2011).  
Disease Age of Onset Locus Name Locus 
Gene 
Symbol Protein Name Topology 
Cellular 
Location 
INCL < 2 years CLN1 1p34.2 PPT1 Palmitoyl protein thioesterase 1 Soluble Lysosomes 
LINCL 1-4 years CLN2 11p115.4 TPP1 Tripeptidyl peptidase 1 Soluble Lysosomes 
JNCL 4-10 years CLN3 16p11.2 CLN3 CLN3/ battenin Membrane Lysosomes 
ANCL 11-50 years CLN4 20q13.33 DNAJC5 Dnaj homolog Membrane ER 
fLINCL 4-7 years CLN5 13q22.3 CLN5 CLN5 Soluble Lysosomes 
vLINCL 1.5-8 years CLN6 15q23 CLN6 CLN6 Membrane ER 
tLINCL 3-7 years CLN7  4q28.2 MFSD8 Major facilitator superfamily Membrane Lysosomes 
EPMR 5-10 years CLN8 8p23.3 CLN8 CLN8 Membrane ER-Golgi 
CLN9 4-6 years CLN9 Unknown n/a Unknown Unknown  
Congenital NCL 0-1 years CLN10 11p15.5 CTSD Cathepsin D Soluble Lysosomes 
CLN11 disease Adult CLN11 17q21.31 GRN Granulins Soluble Extracellular 
CLN12 disease Juvenile CLN12 1q36.13 ATP13A2 Probable cation-transporting Membrane Lysosomes 
CLN13 disease Adult CLN13 11q13.2 CTSF Cathepsin F Soluble Lysosomes 
CLN14 disease Infant CLN14 7q11.21 KCTD7 *BTB/POZ domain-containing Soluble Cytosol 
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While not everything is known about CLN1, CLN2 and CLN10, even less is known 
about the remaining forms of NCL. For the most part, the specific genes and proteins 
are known, but there is only speculation about the function of these proteins or the 
role in lysosomal degradation (Nita, et al., 2016). Generally, these proteins are 
membrane bound and therefore typically more difficult to characterise. Although also 
being a soluble (non-membrane bound) protein, the function of CLN5 is unknown. 
CLN5, or Finnish late-infantile NCL may arise from one of 46 known mutations in 
the CLN5 gene (UCL, 2017). Not a lot about the 407-amino acid protein is known 
(Savukoski, et al., 1998). What is known is that it is directed to the lysosome 
(Isosomppi, et al., 2002), and has some interactions with CLN2 and CLN3 (Vesa, et 
al., 1995). This suggests that there is an important interaction or a common molecular 
pathway (Nita, et al., 2016). CLN3, or juvenile-onset NCL is caused by one of at least 
57 identified mutations on the CLN3 gene (encoding CLN3 or Battenin) (UCL, 2017) 
and is the most common form of Batten disease (Batten Disease Consortium, 1995). 
CLN3 is found predominantly in the endolysosome system, although it is also found 
in the Golgi, cell membrane and mitochondria (Phillips, et al., 2005).  In most cases 
of CLN3, there is a 1kb deletion, which is of northern European origin (Munroe, et 
al., 1997), where there is some remaining activity (Kitzmuller, et al., 1997). There are 
many potential functions of the CLN3 protein, including aiding processing of 
mitochondrial membrane proteins (Margraf, et al., 1999), lysosomal pH regulation 
(Golabek, et al., 2000), transporting amino acids into the lysosome (Holopainen, et 
al., 2001), lysosomal size (Ramirez-Montealegre & Pearce, 2005) and apoptosis 
(Puranam, et al., 1999) among others. CLN4, or adult-onset NCL and also known as 
Parry’s disease is caused by two mutations in the DNAJC5 gene (DnaJ heat shock 
protein family [Hsp40], member C5) (Nosková, et al., 2011; Benitez, et al., 2011). 
Unlike the other forms of the disease, CNL4 is autosomal dominant. CLN4 is 
accountable for 1.3% – 10% of NCL cases (Sadzot, et al., 2000), with an onset of 6 
years to 62 years old with variable pathologies. CLN4 differs from all other forms of 
NCL not only in the delayed onset, but also in the absence of the loss of vision to 
patients (Berkovic, et al., 1988). CLN6, or early juvenile/late infantile-onset NCL, is 
caused by one of 68 mutations (UCL, 2017) in the CLN6 gene (Sharp, et al., 1999; 
Gao, et al., 1999), of unknown function.  What is known is that the CLN6 encoding 
protein is a membrane bound protein with seven transmembrane domains (Sharp, et 
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al., 2003; Heine, et al., 2007), which is localized to the endoplasmic reticulum (ER) 
(Heine, et al., 2004). It is suggested however, that because it localizes to the ER, that 
its function may be involved with the transport of proteins and fats from the ER to the 
lysosomes (Genetic Home Reference, 2017). The onset of CLN6 varies largely from 
18 months of age to 8 years of age, and usually has a fast disease progression. CLN7, 
or variant late infantile onset NCL is caused by one of at least 31 mutations in the 
CLN7, or MFSD8 protein (UCL, 2017). MFSD8 is part of the major facilitator 
superfamily of proteins (Siintola, et al., 2007). It is a 518-amino acid membrane 
bound protein with a predicted 12 transmembrane domains (Siintola, et al., 2007; 
Steenhuis, et al., 2010), and is thought to transport substrates such as sugars, drugs 
and cations through chemiosmotic gradients within the lysosome (Jalanko & Braulke, 
2009; Pao, et al., 1998; Kousi, et al., 2009). Age of onset is 2 – 7 years and also has 
rapid disease progression. CLN8 is also known as EPMR (progressive epilepsy with 
mental retardation) or northern epilepsy (Ranta, et al., 2004; Ranta, et al., 1999). One 
of at least 33 mutations in the CLN8 gene result in the disease (UCL, 2017; 
Reinhardt, et al., 2010). CLN8 is a 286-amino acid protein polytopic membrane 
protein, which moves between the ER and Golgi-ER intermediate complex (Lonka, et 
al., 2000). Its functions are unknown, however it may be involved in metabolism, 
biosynthesis, transport and detection of lipids, as it is a member of TLC (TRAM-
Lag1p-CLN8) protein family (Jalanko & Braulke, 2009). Age of onset is in childhood 
between 5 and 10 years, and patients live to between 50 and 60 years old.  
 
Even less again is known about the remaining, very recently identified forms of NCL. 
CLN9 is proposed to be a unique NCL entity, however no gene has yet been 
identified. It is suggested that it is independent from all other forms of NCL due to 
distinctive fibroblast phenotypes (rapid growth, sensitivity to apoptosis, cell adhesion 
deficiency and reduced ceramide, dihydroceramide and sphingomycin) (Schulz, et al., 
2004; Schulz, et al., 2006). The disease is clinically indistinguishable from CLN3 
(Haddad, et al., 2012).  Even more recently, several other protein mutations have been 
identified as causative factors of NCL. One of two mutations (UCL, 2017) in 
granulins (GRN) results in CLN11 (Hafler, et al., 2014; Canafoglia, et al., 2014). 
Mutations in GRN have previously been known to cause frontotemporal lobe 
dementia (Smith, et al., 2012). A single mutation in ATP13A2 – which is believed to 
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be a cation transporting protein (Tang, et al., 2006) – has been identified as the 
causative mutation in CLN12 (UCL, 2017). Mutations in ATP13A2 have also been 
found to cause Kufor-Rakeb syndrome, a juvenile form of Parkinson’s disease (Bras, 
et al., 2012).  CLN13, an adult onset NCL, is caused by one of 6 mutations in 
cathepsin F (CTSF) (UCL, 2017; Smith, et al., 2013). CTSF is a member of the 
papain family of cysteine proteinases, which account for a major component of the 
lysosomal proteolytic family. Finally, CLN14 is caused by one of 13 mutations of 
BTB/POZ domain-containing protein KCTD7 (potassium channel tetramerization 
domain-containing protein 7) (UCL, 2017; Staropoli, et al., 2012).  
 
All in all, there are collectively many facets of the disease. While it is still unclear 
whether or not these responsible proteins interact with one another via a common 
pathway, there are unmistakable similarities between them on a cellular and 
symptomatic level. A better understanding of each individual form of the disease is 
beneficial to all other forms of the disease and cellular processes as a whole.  
 
1.4 Biology of NCL 
Although the varying forms of NCL are somewhat diverse in their clinical 
presentation and their age of onset, they are grouped together based on the 
accumulation of autofluorescent pigments in the neuronal and extra neuronal tissue. 
Originally, it was thought that the existence of these storage bodies were, in fact the 
reason for the neurodegradation. It is now, however, understood that this 
accumulation of highly hydrophobic materials is just a by-product of the dysfunction 
in one or more pathways critical for neural cell survival. This is best proven by the 
fact that, while the disease state leads to the accumulation of these materials in cells 
throughout the body, there is only a detrimental outcome to the neuronal cells 
(Claussen, et al., 1992; Jarplid & Haltia, 1993). Neuronal cells have limited capacity 
for regeneration, are much more sensitive to cell damage and there is an imperative 
need for prolonged neuronal survival (Collins, et al., 1989; Huebner & Strittmatter, 
2009). Despite this knowledge, the relation of these altered proteins to the clinical 
symptomology is unknown. Several different routes of neuronal degradation have 
been hypothesized such as apoptotic (Lane, et al., 1996; Riikonen, et al., 2000) and 
exocitotoxic mechanisms (Walkley, et al., 1995) and the possibility that all NCL 
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genes are collectively involved either directly or indirectly with the same trafficking 
pathway, which is vital to neurons (Zhong, 2000).  
 
Using a CLN6 ovine model, the contents of these autofluorescent storage bodies had 
been analyzed to find that around two thirds of the storage bodies are made up of the c 
subunit of ATP synthase complex, with the remainder being mostly made up of lipids 
(Palmer, et al., 1986; Palmer, et al., 1989). Following this discovery, subunit c has 
been identified as the main contributor to these storage bodies in most forms of NCL, 
including CLN2, CLN3, CLN5, CLN7 and CLN8 (Faust, et al., 1994; Herva, et al., 
2000; Kominami, et al., 1992; Palmer, et al., 1992; Tyynela, et al., 1997). This is, 
however not the case in the CLN1, CLN4 and CLN10 forms of the disease, where 
sphingolipid activator proteins (SAPs) A and D have been reported to be the main 
contributor to the storage body contents (Chen, et al., 2004; Nijssen, et al., 2003; 
Tyynela, et al., 1993; Tyynela, et al., 2000). The contents of the storage bodies for the 
remaining forms of NCL have either not been analyzed or vary throughout different 
parts of the body or brain. As for the autofluorescent nature of the storage bodies, no 
intrinsic flurophore has been identified among the components. Reconstruction of 
storage body from non-fluorescent subunit c and sheep liver phospholipids have 
confirmed that this observed autofluorescence is an aggregate, and not an intrinsic 
entity (Palmer, et al., 2002). The existence of common storage body occupants 
suggests that there is perhaps a common pathway and that the different NCL proteins 
interact with one another. Several studies have explored this possibility (Zhong, et al., 
2000; Vesa, et al., 2002; Lyly, et al., 2009), and there is some indication of an 
interaction with CLN2 and CLN3 with CLN8, however techniques used in these 
studies are not perfected and so findings must not be taken as an absolute.   
  
Autophagy is induced in several forms of NCL diseases, as observed in mouse 
models, and could be the method responsible for triggering cell death. In CLN10, the 
amount of autophagic vacuoles is increased in Cln10 knock-out mice compared to 
wild type and an increase in autophagosome-associated LC3-II has been reported 
(Koike, et al., 2005). Another study has suggested that there is a disruption in 
autophagic vacuolar maturation in CLN3, and that the activation of autophagy (also 
shown by an increase in LC3-II) is a pro-survival feedback response in the disease 
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(Cao, et al., 2006). Finally, CLN6 is thought to have impaired fusion between 
autophagosomes and lysosomes. In one study, it was suggested that the disease, 
leading to an impairment in autophagy, in turn promotes cell degradation through the 
formation of p62 positive aggregates, which are toxic to cells (Thelen, et al., 2012). 
 
Other studies have shown that endocytosis and trafficking may be responsible for 
neurodegeneration. This is based on the fact that deficits in endocytosis and 
membrane trafficking observed in some forms of NCL could be particularly 
detrimental to neuronal cells only. As neurotransmission is highly dependent on 
membrane vesicle transport, a disruption to this may have a large impact on the 
neurons. Defects in endocytosis and trafficking have been reported in CLN3. A recent 
study’s findings have suggested that the gene responsible for CLN3, BTN1, is 
involved in maintaining Golgi integrity and in retrograde transport from the 
endosomal compartment to the Golgi – therefore this pathway may be adversely 
affected in CLN3 (Kama, et al., 2011; Uusi-Rauva, et al., 2012). There is also some 
information suggesting that endosomal pathway has also been similarly affected in 
CLN5 (Mamo, et al., 2012) and CLN1 (Ahtiainen, et al., 2006). Relating to this, 
defects have been identified in synaptic trafficking for CLN1, CLN4 and CLN10 as 
well as increasing evidence that early synaptic failure is involved in pathogenesis 
(Kim, et al., 2008; Sharma, et al., 2012; Koch, et al., 2011).  
 
There is some indication that inflammation may play an important role in 
neurodegeneration. The localized activation of microglial cells and astrocytes have 
been observed to be closely related to disease pathogenesis, first in the thalamus then 
followed by the corresponding cortical regions (Schmiedt, et al., 2012; Macauley, et 
al., 2011). Neural inflammation has been shown to precede neurodegeneration in the 
CLN6 ovine model (Oswald, et al., 2008; Tammen, et al., 2006), and is even seen in 
affected models prenatally (Oswald, et al., 2005; Kay, et al., 2006). It is also possible 
that glial function is in fact implicated in the disease state and may also be responsible 
for the death of neurons (Pontikis, et al., 2004). Furthermore, with neuroinflammation 
the blood brain barrier (BBB), which usually blocks components of the adaptive 
immune response such as leukocytes from entering the brain, may be compromised. 
This means these leukocytes may activate and release further inflammatory factors 
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and therefore add to the neuroinflammation and possible neurodegeneration (Das & 
Basu, 2008). The existence of such inflammation is evident by the increase of several 
proteins observed across various forms of NCL. This includes glial fibrillary acidic 
protein (GFAP), an intermediate filament that is representative of astroglial activation 
and gliosis during neurodegeneration (Brahmachari, et al., 2006; Xu, et al., 2010; 
Pontikis, et al., 2004), cluster of differentiation 68 (CD68), a protein highly expressed 
in monocytes and macrophages (Holness & Simmons, 1993; Pontikis, et al., 2004) 
and nitric oxide synthases (NOS) (Nakanishi, et al., 2001). The mechanism of 
inflammatory function in neurodegenerative diseases is, however, the topic of some 
debate, as it has been shown to have both neuroprotective and neurodegenerative 
outcomes (Beal, 2001; Hirsch & Hunot, 2009; Vila, et al., 2001).  
 
There are many contributing factors in the disease progression. It is likely that the low 
tolerance for neuronal loss with the addition of chronic inflammation aggravating 
further neuronal loss results in the disease pathology (Boustany, 2013). There are 
many other biological factors that may be involved in NCL, which may or may not be 
involved in the neurodegeneration, such as apoptosis, lipid metabolism and 
endoplasmic reticulum stress etc. This outlines just how little is known about the 
disease process and the correct route for treatment. 
 
1.5 Current Therapies and Obstacles 
As stated previously, most treatment of any form of Batten disease is symptomatic 
and supportive. These treatments vary from patient to patient as do the symptoms of 
the disease. There are many antiepileptic, anticonvulsant, behavioral and anti-
depressant drugs that may be used, and supportive treatments such as occupational 
and physical therapy, speech therapy, suction and airway support, feeding 
gastrostomy and caregiver support (Geraets, et al., 2016). These treatments may 
improve the quality of life for the patients and families, however they do not alter the 
outcome of the disease.  
 
However, as of April this year (2017) the FDA (U.S. Food and Drug Administration) 
has approved the first ever drug specifically for the treatment of Batten disease. 
Brineura (cerliponase alfa) has been approved for the treatment of CLN2 patients 3 
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years and older (FDA, 2017). Brienura is a form of recombinant human TPP1 enzyme 
used to amend the dysfunction of the protein in CLN2 patients. A phase I/II, 
multicenter, open-label, dose-escalation study has found that the treatment is well 
tolerated and effectively slows the progression of the functional decline suffered by 
CLN2 children (Schulz, et al., 2016; Schulz, et al., 2017). 
 
Gene therapy, stem cell therapy, dietary supplements, small molecule therapy and 
enzyme replacement therapy are the main methods being considered for the treatment 
of NCLs. Gene therapy is based on introducing a population of viruses harboring a 
normal copy of the affected gene to over-produce the protein and secrete it into 
surrounding cells. Adeno-associated virus (AAV) and lentivirus (LV) are commonly 
used in NCL gene therapy research. Promising results have been observed in small 
animal models for CLN1, CLN2 and CLN10 (Macauley, et al., 2012; Roberts, et al., 
2012; Sondhi, et al., 2007; Shevtsova, et al., 2012) as well as CLN2 (Sondhi, et al., 
2012), CLN5 and CLN6 (Neverman, et al., 2015) in large animal models. There are 
also currently three gene therapy clinical trials running for: scAAV9.CB.CLN6 in 
CLN6 (NCT02725580, Clinicaltrials.gov), AAVrh.10.CB.CLN2 (NCT01414985, 
Clinicaltrials.gov) and AAVrh.10.CB.hCLN2 (NCT01161576, Clinicaltrials.gov) in 
CLN2. Following the favourable results in LSD mucopolysaccaharidosis 1 using stem 
cell therapy, the approach has been considered in NCLs (Hopwood, et al., 1993). This 
approach is based on healthy compatible human stem cells being administered to NCL 
patients, where the monocytes will migrate to the area of interest and produce then 
secrete normal copies of the affected protein to be taken up by surrounding cells 
(Vellodi, 2005). For this reason, only soluble proteins may be considered. Although 
this approach does not reverse clinical symptoms, it may be used in conjunction with 
other therapies. Several studies have been carried out using stem cell therapy on 
NCLs. In CLN1 PPT1 activity was normalized in leukocytes (Lonnqvist, et al., 2001) 
this was followed by a clinical trial for HuCNS-SC stem cells in CLN1 and CLN2 
patients (Tamaki, et al., 2009; NCT00337636, Clinicaltrials.gov). Studies in CLN2 
and CLN3 have shown minimal benefits (Lake, et al., 1997). Antioxidant dietary 
supplements have also had some traction in the treatment of NCLs. Although 
oxidative stress is not a primary defect in NCL cells, there is some indication that 
antioxidants provide some benefits and could also be used in conjunction with other 
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treatments. Antioxidants vitamin E (Griffin, et al., 2002), resveratrol (Yoon, et al., 
2011; Wei, et al., 2011; Saha, et al., 2011), endoplasmic reticulum modifiers TMAO 
(trimethylamine N-oxide) and TUDCA (tauroursodeoxycholic acid) (Wei, et al., 
2008) and NtBuHA (Sarkar, et al., 2013) have all shown some clinical promise. 
Several forms of small molecule therapies are also being researched for NCLs. 
Chemical chaperone therapy attenuates the abnormalities in protein folding by 
missense mutations (therefore is limited to protein malfunction via missense mutation 
only). This method has been successful in LSDs Fabry disease (Frutaci, et al., 2001), 
Gaucher disease (Sawkar, et al., 2002), and GM-1 gangliosidosis (Matsuda, et al., 
2003). This approach is being investigated in CLN1 and CLN2 using high 
concentration thiols, such as N-acetylcystine and cystamine (Zhang, et al., 2001; Lu, 
et al., 2006). Another form of small molecule therapy via substrate reduction (in 
conjunction with enzyme replacement) has shown favourable results in the metabolic 
disease glycospingolipidoses (Vellodi, 2005) and is being investigated in CLN1 
(Levin, et al., 2014). In another approach, the clearance via ‘ER quality control 
system’ may be avoided by pharmacological chaperones, as shown in CLN1 
(Dawson, et al., 2010). In this approach, misfolded proteins as a result of missense 
mutations may be salvaged and residual protein function is obtained (Valenzano, et 
al., 2011).  
 
Some hypothesis-driven treatment methods have also been considered. Flupirtine 
maleate, an antiapoptotic drug, has been used for the treatment of various forms of 
NCL, although has yet to have any clinical studies conducted on the efficacy (Dhar, et 
al., 2002).  Likewise, phosphocysteamine, a drug which breaks ester linkages, has 
been used in the treatment of CLN1. The theory is that phosphocysteamine activity 
may amend the loss of PPT1 protein. However, for this drug too, there has not been 
any reporting of a definitive improvement to patients (Zhang, et al., 2001). Lithium 
has also been suggested in the treatment of CLN3. It is presumed to be an enhancer of 
autophagy and has been shown to reduce lipid storage in cerebellar cells from CLN3 
knock-in mice (Chang, et al., 2011) although, this treatment is limited by the 
nonspecific targeting of lithium. Lipid lowering drugs have also been proposed in the 
treatment of CLN2. Gemfibrozil and fenofibrate have both been shown to upregulate 
TPP1 in CLN2 mice (Ghosh, et al., 2012). These treatments and other potential 
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hypothesis-driven treatments require the knowledge of normal protein function to 
have a clinical affect on NCL patients, which we do not have for the majority of the 
forms of the disorders. This route of treatment requires extensive investigation into 
the pathology of each individual form of NCL followed by either drug screening or 
drug formulation. All in all, potentially taking decades of research.  
 
Non-steroidal anti-inflammatory or immunomodulatory approaches have shown 
beneficial outcomes in other LSD mouse models (Koeberl & Kishnani, 2009; Ma, et 
al., 2007). Anti-inflammatory drug mycophenolate mofetil has shown a decrease of 
neuroinflammation, deposition of immunoglobulin G in the brain and protection of 
vulnerable neuron populations as well as improved motor skills in Cln3-defecient 
mice (Seehafer, et al., 2011). These findings contributed to the phase II clinical trial 
of mycophenolate mofetil for the treatment of CLN3 (NCT01399047, 
Clinicaltrials.gov). This demonstrates the large role inflammatory responses may play 
in disease process in at least some forms of NCL and poses a very viable passage for 
treatment.  
 
Besides the obvious unknown nature of many aspects of Batten disorders, there are 
several other major treatment obstacles for patients and research. The rarity and 
diverse nature of the disease makes it difficult to yield meaningful differences 
between treatments and controls in clinical trials. Delivering drugs to the brain on its 
own is an obstacle. In the case of gene therapy, the transition of animal studies into 
humans can be difficult due to differing brain sizes, there may be difficulty obtaining 
biodistribution and a good method of delivery. The BBB is of particular impediment 
for drug delivery and with the addition of the need for targeted delivery to specific 
cells or lysosomes creates a difficult hurdle or overcome. The FDA approved drug 
Brineura must be administered into the cerebrospinal fluid (CSF) via infusion. This 
requires a surgical implanted reservoir and catheter to be inserted into the head. With 
this there is high risk of infection. Doses must be administered every two weeks by a 
healthcare professional in a sterile environment (FDA, 2017). Timing of treatment can 
be an obstacle in neurodegenerative diseases. By the time the disease has been 
diagnosed, a great deal of neurodegeneration has already occurred. The fact that 
lysosomal storage bodies are observed prenatally demonstrates this. The timing of 
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diagnosis and the beginning of treatment can improve the outcome of disease 
symptoms. In the cases of enzyme replacement therapy and gene therapy, there is a 
risk of acquiring immunological resistance against the enzymes overtime. This 
phenomenon has been observed in other LSDs (Messinger, et al., 2012) and could 
very likely happen in NCL patients, although effects may be attenuated with the early 
use of immune-modulating agents such as methotrexate or rituximab (Desnick & 
Schuchman, 2012). These obstacles are additional to the usual obstacles encountered 
with any sort of disorder that requires treatment – the access therapy. This includes 
the high costs of these treatments and access to particular heath care facilities and 
professionals. 
 
1.6 Animal Models 
Fortunately, there are several animal and other small organism models for many 
forms of NCL that help fill in some of gaps in information about the diseases as well 
as investigate therapies. Small biological model systems exist for CLN2, CLN10 and 
CLN11 in zebrafish (Mahmood, et al., 2013; Follo, et al., 2013; Chitramuthu, et al., 
2010; Laird, et al., 2010), for CLN1, CLN3, CLN10, CLN7 and CLN4 in Drosophila 
(Hickey, et al., 2006; Tuxworth, et al., 2011; Myllykangas, et al., 2005; Faller, et al., 
2015; Zinsamaier, et al., 1994; Umbach, et al., 1994) and for CLN1, CLN3, CLN10 
and CLN12 in yeast (Faller, et al., 2015). These systems are very cheap, easily 
maintained and have a high reproductive rate. They provide extremely valuable 
biological tools to investigate protein functions and collect preliminary information 
prior to investigating therapies. Naturally occurring cases of NCLs have been 
observed in many species of animals, and may provide beneficial larger system 
models for disease and treatment. These include cattle (Houweling, et al., 2006), 
horses (Url, et al., 2001), pigs (Cesta, et al., 2006), goats (Fiske, et al., 1988), at least 
15 different breeds of dogs (Awano, et al., 2006; Katz, et al., 2005), cats 
(Weissenbock, et al., 1997; Nakayana, et al., 1993), ferrets (Nibe, et al., 2011), birds 
(Evans, et al., 2012; Reece & MacWhirter, 1988) and monkeys (Jasty, et al., 1984). 







1.6.1 Mice  
Mouse models provide an invaluable resource in any form of therapeutic or protein 
function research. They are relatively cheap, easy to handle and have a high 
reproductive rate. They provide a logical progression from smaller systems such as 
Drosophila or yeast, to study disease mechanisms and progression of disorders in a 
more complex system and are absolutely essential for preclinical testing. In total, 
there are 12 mouse models for NCLs and they are both naturally occurring and 
genetically modified. The genetically modified forms include NCL models for 
CLN10 (Saftig, et al., 1995), two for CLN1 (Gupta, et al., 2001; Jalanko, et al., 
2005), CLN2 (Sleat, et al., 2004), CLN5 (Kopra, et al., 2004), four for CLN3 
(Cotman, et al., 2002; Eliason, et al., 2007; Katz, et al., 1999; Mitcheson, et al., 1999) 
and CLN7 (Damme, et al., 2014). There are also two identified naturally occurring 
NCL mouse models for CLN6 (Bronson, et al., 1998) and CLN8 (Bronson, et al., 
1993).  All of these models exhibit key biological and phenotypic features of the 
human forms of NCL and each model possesses autofluorescent storage bodies 
(Faller, et al., 2015). Of particular interest is the naturally occurring CLN6 mouse 
model, or Cln6nclf. First described in 1998, the gene mutated in Cln6nclf was found to 
be in between D9Mit164 and D9Mit165. This region is homologous to human Ch 
15q21, where the gene responsible for CLN6 is located (Bronson, et al., 1998). The 
mice were observed to develop hind-limb paralysis at around 8 months of age, which 
is followed by death at around 1 year (Bronson, et al., 1998). The appearance of 
intracellular inclusions are detected as early as 11 days of age and the mice also suffer 
retinal degeneration as young as 6 months of age. This mirrors the early onset of the 
human form of the disease (Bronson, et al., 1998; Wheeler, et al., 2002). The loss of 
CLN6 function in the Cln6nclf mouse model has been shown to lead to the disruption 
of synaptic function (Kielar, et al., 2009), a disruption in autophagy-lysosome 
degradation pathway (Thelen, et al., 2012) and linked to deficits in biometal 
homeostasis (Kanninen, et al., 2012), among other potential causative factors which 
may be homologous to the human form of the disease. A recent extensive and detailed 
Cln6nclf characterisation study has outlined the efficacy of this model for translational 
research in CLN6 (Morgan, et al., 2013). The study shows both the behavioral and 
pathological similarities between Cln6nclf mice and the human form of the disease. 
These similarities include deficits in motor coordination, vision, memory and learning 
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as well as specific loss of neurons in sub-regions and lamina of the cortex, which 
correlate to the behavioural phenotypes (Morgan, et al., 2013). These findings further 
validate the efficacy of the Cln6ncl model to simulate the human form of the disease. 
 
1.6.2 Sheep  
Ovine models provide a further progression in NCL research. The brain weights are 
more similar to human brain weights (mouse = 0.5 g, sheep = 175 g, 5-year-old child 
= 450 g), they have a longer life span and they provide a more similar profile of 
disease pathology as well as a more compatible anatomy and physiology to humans. 
(Frugier, et al., 2008; Jolly, et al., 1992). The first ovine model for NCL was observed 
in New Zealand in 1976 in South Hampshire sheep (Jolly & West, 1976). It was later 
identified to be CLN6 deficient and this flock has been maintained since (Getty & 
Pearce, 2011; Tammen, et al., 2006). A similar mutation in the same gene was later 
identified in merino sheep in 2002, and a flock of these sheep has also been 
maintained (Cook, et al., 2002). Both models show symptoms at 8 – 12 months, and 
disease symptoms and pathology are defined as blindness, motor deficits, tremors and 
autofluorescent storage material, paralleling the human form of disease (Getty & 
Pearce, 2011; Cook, et al., 2002). These models provide the opportunity to better 
study therapies on a more human-like disease model.  
 
1.7 Cannabis   
Cannabis may be one of the oldest cultivated plants in the world (Russo, 2007). The 
earliest written account of the medicinal use of cannabis dates back to the 6th century 
(Long, et al., 2016) and is well documented for its use in tetanus and other convulsive 
diseases in the 19th century (O’Shaughnessy, 1840). Following its long medicinal use, 
its preparation was added into the Pharmacopedia of the United States for its 
analgesic, hypnotic and anticonvulsant properties (Russo, 2007; U.S. Pharmacopoeial 
Convention, 1916) before its subsequent removal and prohibition in 1937. Cannabis 
research has become increasingly more popular in recent years. It is readily available 
and the safety of use is well documented. Not only in the healthcare system has 
cannabis been a hot topic, but also in the political arena. Since its widespread 
prohibition in the late 1930s, it has only recently become legal for medicinal use and 
even decriminalised for recreational use in several US states.  Its use has also become 
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legal for medical use in as many as 29 countries as of 2017. Many other countries 
may join these soon with legislation likely to be passed in the immediate future. A 
simple search of cannabis in PubMed will show almost a third of total papers on the 
topic have been published within the last 5 years (PubMed.gov, 2017). While it has 
always been a contentious issue, there certainly appears to be more and more public 
pressure on governments as well as an increase in cannabis research – and for good 
reason too, it has many favorable properties in the treatment of a wide range of 
disorders and illnesses.  
 
1.7.1 Components and properties 
While there are at least 60 cannabinoids identified in the cannabis plant to date 
(Elsohly & Gul, 2014), cannabidiol (CBD) and delta-9-tetrahydrocannabinol (Δ9-
THC) are the most abundant. These two cannabinoids are made from the same pre-
cursor cannabinoid, cannabigerolic acid (CBGA) from olivetolic acid (Figure 1.) and 
their proportions vary dependent on the strain of cannabis. It was following the 
isolation of Δ9-THC and synthesis of synthetic molecules that the cannabinoid 
receptors CB1 and CB2 were discovered (Devane, et al., 1988). They are both 
activated by Δ9–THC or other agonists and initiate a complex pathway. The binding 
causes inhibition of adenylyl cyclase activity, which in turn closes voltage-gated 
potassium channels. There is then an inward opening of potassium channels to rectify 
this change, which stimulates mitogen-activated protein kinases such as extracellular 
signal regulated kinases and focal adhesion kinases (Mackie, 2006). High numbers of 
CB1 and to some extent CB2 receptors have been localized to regions in the brain that 
regulate appetite, memory, fear, motor responses and posture (Mackie, 2006). This 
explains the psychoactive and other effects of Δ9-THC. On the other hand, CBD is not 
a cannabinoid receptor agonist and lacks the cannabis-like intoxication of Δ9-THC. 
CBD only has low CB1 and CB2 affinity (Thomas, et al., 2007) and may even 
negatively modulate CB1 receptors via an allosteric mechanism (Laprairine, et al., 
2015). CBD is however, a known 5-HT1A receptor (5-hydroxytryptamine 1A) and 
TRPV1 receptor (Transient receptor potential vanilloid type 1) agonist (Russo, et al., 
2005; Bisogno, et al., 2001). In addition, CBD can also enhance adenosine receptor 
signaling via a negative feedback loop of its inhibition of adenosine inactivation. It is 
this action of CBD on these receptors, which generate CBD’s role in pain relief and 
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inflammation (Carrier, et al., 2006). This antioxidant and anti-inflammatory activity 
of CBD may also provide an explanation for the neuroprotective application of the 























Figure 1.1 Synthetic pathway of cannabinoids Δ9-Tetrahydrocannabidiol and 
cannabidiol from their common precursor cannabinoid cannabigerolic acid and 
olivetolic acid (National Academies of Sciences, Engineering, and Medicine, 2017).  
 
1.7.2 Current uses 
There are seemingly endless potential applications of cannabis in the medical field. 
These include, but are not limited to: cancer, chronic pain, nausea and vomiting, 
anorexia and weight loss, irritable bowl syndrome, epilepsy, spasticity, Tourette 
syndrome, amyotrophic lateral sclerosis, Huntington’s disease, Parkinson’s disease, 
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dystonia, dementia, glaucoma, brain injury or intracranial hemorrhage, addiction, 
anxiety, depression, sleeping disorders, post traumatic stress disorder, schizophrenia 
and other forms of psychosis (National Academies of Sciences, Engineering, and 
Medicine, 2017). To date there are three drugs based on cannabinoids, which have 
been approved by the FDA. The first of these was dronabinol (trade name Marinol®), 
a synthetic form of Δ9–THC. It is used for nausea and vomiting induced by 
chemotherapy in cancer patients and to stimulate appetite in AIDS patients. The 
second, also a synthetic form of Δ9–THC, is nabilone (trade name Cesamet®), which 
is used for similar applications to dronabinol. Both of these formulations are 
administered orally via capsules. The third is an oral solution of dronabinol under the 
trade name Syndros®. There are two other cannabis-based drugs of particular interest 
to the FDA. Nabiximols (trade name Sativex®), is an ethanol based one to one ratio 
formulation of both Δ9–THC and CBD. The oral spray is used for symptoms of 
multiple sclerosis and an analgesic for cancer patients (Pertwee, 2012). Nabiximols 
has already been launched in 15 countries including United Kingdom, Germany and 
Canada and has been approved in additional 12. Finally, the only cannabinoid-based 
medication to contain only CBD - Epidiolex®. The drug, formulated by the same 
company as Sativex®, is a highly concentrated CBD oil (>98% pure) developed as an 
anti-seizure medication which has shown a reduction in convulsive-seizure frequency 
in patients with Dravet syndrome (Devinsky, et al., 2017).  As of June of 2017, it has 
been approved for medicinal use in New Zealand. 
 
1.7.3 Cannabidiol for Batten disease 
While cannabis for the treatment of seizures is well documented, there are few studies 
with NCL patients included. In one such study, one 8-year-old boy was given 0.7 
mg/kg Δ9–THC (no CBD) daily until his death 7 months later. There was a noticeable 
reduction in spasticity and the child appeared happier. The anti-epileptic effect was 
unable to be assessed due to the boy’s previous anti-seizure medications (Lorenz, 
2004). Another study looked at seizure frequency in a number of disorders, including 
NCLs, with the treatment by CBD (Devinsky, et al., 2016). While a promising 
reduction in seizure frequency was detected, both of the NCL patients included in the 
study were in the safety assessment group (Devinsky, et al., 2016). Additionally, a 
patent application has reported a significant reduction in focal seizures in NCL 
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patients among other seizure suffers (Guy, et al., 2015). Further to the anti-seizure, 
analgesic and anti-depressant activity of CBD (Cunha, et al., 1980; Burns, et al., 
2006; Whiting, et al., 2015), there are additional actions of the drug, which may also 
be extremely valuable in treatment of NCLs – anti-inflammation and neuroprotection. 
Antioxidants are effective in neuroprotection due to their ability to clear toxic reactive 
oxygen species (ROS). In normally functioning healthy cells, ROS are a normal 
product of cellular metabolism and endogenous antioxidant systems are able to clear 
these ROS to maintain a healthy, functioning cell (Halliwell, 1994). In 
neurodegenerative diseases, there is a functional loss due to some form of cellular 
stress. This means that ROS are not being cleared and therefore contributing to 
cellular dysfunction. The overproduction of free radicals causes detrimental oxidative 
damage to lipids, proteins and DNA and therefore disrupts cell functions and induces 
inflammation. Taken together this contributes further to the neurodegeneration. For 
this reason, antioxidative species are beneficial to neurodegenerative disorders such as 
NCLs (Uttara, et al., 2009). CBD and Δ9 –THC have been shown to prevent both 
glutamate neurotoxicity and ROS-induced cell death in vitro (Hampson, et al., 1998). 
This effect was not diminished by the addition of cannabinoid receptor antagonist 
(Hampson, et al 1998). Although CBD is not a cannabinoid receptor agonist, it was 
first thought that the neuroprotective action of cannabis was in fact by the activation 
of these receptors (Skaper, et al., 1996). It is now understood that the anti-oxidative 
effect is independent of this pathway (Mansbach, et al., 1996, Hampson, et al., 1998). 
Considering the fact that both CBD and Δ9–THC have the same magnitude of 
neuroprotective activity, it is likely that the neuroprotection is attributed to a 
downstream action of initial receptor agonism (Hampson, et al 1998; Hampson, et al., 
2000). CBD also has anti-inflammatory activity, which is of great relevance to NCL 
treatment. While the precise mechanism of anti-inflammation by CBD is unclear, it 
does reduce the production of pro-inflammatory cytokine TNF-α and induces the 
reduction of fatty acid amino hydrolase activity and therefore increasing the 
production of anandamide, which is an anti-inflammatory endogenous cannabinoid 
(Zurier, et al., 2016). Pyrolysis products of CBD have also shown to have activity in 
COX-1-supression assays – i.e. have some activity in the antagonism of COX-1 and 
thus potentially anti-inflammatory (Spronck, et al., 1978). The anti-inflammatory 
effects of CBD have been shown in several animal model cases. For example, CBD 
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has been shown to reduce acute inflammation in a mouse model of collagen-induced 
arthritis (Malfait, et al., 2000) as well as in a carrageenan-induced paw edema model 
of acute inflammation in rats (Sofia, et al., 1973). As Δ9–THC has psychoactive 
activity, which is known to interfere with neuronal development (Sundram, 2006); it 
would therefore be inappropriate to give in the treatment of a childhood disease such 
as NCL. With the above considerations, it would be beneficial to test the effects of the 
non-psychoactive cannabis-derived cannabinoid, cannabidiol alone for the potential 
treatment of the pain, seizures and depressive symptoms of the NCL disorders, as well 
as in the cellular pathology of the disorders. 
 
1.8 Voluntary Oral Dosing 
Oral dosing in humans is the most commonly used method of drug administration due 
to its convenience and being economically effective. Voluntary oral dosing, or 
alternate oral dosing, is the oral administration of a drug or drugs to a mouse or other 
animal model via a sweet edible formulation. The theory behind it is to diminish the 
risk of physical and psychological injury to the animal model, which may occur in 
classical dosing methods such as in injection and oral gavage. These potential injuries 
may also negatively impact the remainder of the study by being detrimental to the 
animal’s health or disturb behavioral assessments. The intragastric gavage is typically 
used in oral dosing. The animal must be removed from its cage, manually restrained 
before a metal tube is introduced into the animal’s esophagus to directly release the 
drug solution into the animal’s stomach. This tube may not be soft, pliable or plastic. 
This is because the animal may bite down on the tube and break it off while inside its 
esophagus. While it is an effective method of introducing a drug to an animal orally, 
great care must also be taken when inserting the gavage so to not insert it into the 
trachea of the animal (Atcha, et al., 2010). Cases have been reported where as many 
as 32% of rats had died due to asphyxia caused by granulomatous inflammation, a 
result of the gavage procedure (Germann & Ockert, 1994). Simply restraining the 
animal can also cause great distress, and this distress has been shown to affect the 
animals for as long as 30 to 60 minutes following the procedure (Bonnichsen, et al., 
2005). In recent years, alternative methods have been investigated in their efficacy for 
the oral dosing of animal models. Chocolate-drug pre-mixed palettes have been 
shown to be effective in drug delivery to rats (Huang-Brown & Guhad, 2002), 
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although this may be limited by the stability of the drug and the interference of 
caffeine in chocolate. Another study used a mixture of neuroleptic drugs and 5% 
sucrose solution administered orally by syringe (Schleimer, et al., 2005). Although 
also requiring physical removal from the cage and restraining, this method displayed 
minimal effects on the animal’s wellbeing. A third, more recent study has also used a 
drug-honey solution, which was found to be effective for drug uptake (Küster, et al., 
2012). Another looked at the efficacy of nut paste, peanut butter and sugar paste – 
finding that sugar paste was a very effective method (Diogo, et al., 2015). Finally, in 
an investigation in rimonabant blockage of CB1 receptors for weight-loss in mice a 
voluntary oral administrative method was used in the form of a drug-jelly formulation 
(Zhang, et al., 2010). Artificially flavored and artificially sweetened jelly was used to 
avoid weight-gain in the mice (method outlined - Zhang, 2011). While this strategy is 
somewhat safer and less technically demanding, it does possess some drawbacks. The 
process is entirely dependent on the cooperation of the animal test subjects. This is 
influenced greatly by the taste and familiarity of the formulation. Animals may have 
to be conditioned to consume the formulation by prior food-deprivation, as well as 
sufficient masking of the taste of the drug and/or vehicles. If executed correctly, this 




1.9 Project Aims 
The aim of this project was to observe the affects of the cannabinoid cannabidiol 
alone on Cln6-deficient mice. Following this, both behavior examination and protein 
examination were performed.  
• Affected and unaffected Cln6nclf mice aged between 1 – 1.5 months were treated 
with jelly containing CBD and/or vehicle for 4 weeks.  
• Behaviour tests will be done 2 days prior to the end of the treatment period. Both 
marble burying and elevated plus maze tests were performed. These are 
classically used as a measure of anxiety, however were used to test if the general 
behaviour of the treated mice differs from the untreated and unaffected mice.  
• Immunohistochemical stains will be performed on left-hemishpere coronal brain 
slices. GFAP (glial fibrillary acidic protein), CD68 (cluster of differentiation 68), 
and nNOS (neuronal nitric oxide synthase) for inflammation, which are increased 
with disease, and DCX (doublecortin) for neurogenesis, which has an unknown 
action with both disease and CBD treatment were assessed. Additionally, 




Chapter Two: Methods 
Cln6nclf mice both unaffected (heterozygous for mutated CLN6 gene) and affected 
(homozygous for mutated CLN6 gene) aged 1 – 1.5 months were treated daily a 
voluntary oral dose of raspberry jelly containing vehicle and a high dose of 25 mg/kg 
or low dose of 10 mg/kg of cannabidiol for a period of 29 days. Near the end of 
treatment, marble burying and elevated plus maze behavioural assessments of mice 
were carried out. On the following, and final day of treatment, mice were dosed 
before a saline perfusion, where brain tissue was collected. The left hemisphere was 
prepared for immunohistochemical staining by slicing into 50 μm coronal sections. 
Sections were stained at various loci for GFAP, CD68, DCX and nNOS as well as 
prepared for autofluorescent imaging of storage matherials.  
 
2.1 Animals, Handling and Treatment Groups 
Animal procedures were reviewed and approved by the Animal Ethics Committee 
(AEC) of the University of Otago under the AEC approval number: 115/15. Animal 
handling and Restricted Veterinary Medicine (RVM) drug usage and administration 
was taught and certified by the Animal Welfare Office (AWO). At the beginning of 
the study all mice were between 1 – 1.5 months of age. The treatment periods were 
staggered in 4 different groups as the appropriately aged mice became available from 
the breeding facility. At the beginning of the treatment, all mice weighed between 
17.9 g and 27.8 g. By the end of the 29-day treatment, all mice weighed between 19.1 
g and 29.8 g. In total, 33 Cln6nclf mice were used. All animals were sourced from the 
Hercus Taieri Resource Unit (HTRU) where they were housed and maintained for the 
majority of the treatment period. Unaffected mice (heterozygous for mutated CLN6 
gene; n = 9) were used for the unaffected control group and 24 affected mice 
(homozygous for mutated CLN6 gene) were used for the affected vehicle control, low 
dose and high dose CBD groups (Table 2.1). An extra mouse was included in the 
unaffected vehicle control group due to a complication at the Taieri animal facility, 
where two of the male mice housed together both lost their ear tags. Each mouse 
received the same treatment and were later confirmed to both be heterozygous for the 
mutated CLN6 gene. Upon arrival, each mouse was separated into individual cages 
for feeding purposes. All cages contained a red transparent dome and shredded paper 









Table 2.1 Summary of treatment groups and animal numbers.  
 
For the first week of treatment, the mice were weighed daily to ensure that the 
treatment did not affect the health of the mouse, or make the mouse gain too much 
weight. Following the first week, mice were weighed on a weekly-basis. No mice 
were excluded from the study at any time.  
 
2.2 Jelly Formulation and Drug Concentrations 
A combination of flavoured jellies and gelatine were used to achieve the desired 
flavour and consistency as a sweet food-based method of treatment. Jelly was made in 
either 25 mL or 50 mL lots. A sugar-free jelly was used as the primary source of 
sweetness and flavor; 1 g of ‘Aeroplane Jelly Lite Raspberry’ jelly powder was used 
per 50 mL of jelly. A second jelly powder, ‘Gregg’s Raspberry Jelly’, was also used 
at 0.5 g per 50 mL of jelly. To add stability 1.5 g of ‘Mckenzies Gelatine Powder’ was 
added per 50 mL of jelly (ingredients listed in Appendix A.). The gelatine enables the 
jelly to be more stable at room temperature and assists the mice in being able to hold 
the jelly while they eat (see Figure 2.1). Each of the jelly and gelatine powders were 
weighed out before adding in equivalent volume hot water (does not need to be 
boiling) and was stirred on magnetic hotplate stirrer (DAIHAN) until powders were 
completely dissolved.  
 
The cannabidiol drug vehicle was comprised of a 1 : 1 : 1 mixture of olive oil (PAMS 
Extra Light), ethanol and TWEEN® 20 (Sigma-Aldrich). For the control group’s jelly 
a stock solution was made and 1.5 mL total was added to each 50 mL preparation of 
jelly. This dosage was based on the amount of jelly and vehicle that a generous-
average sized mouse would receive had it contained CBD. Prior to the addition of the 
vehicle solution the jelly mixture was cooled to avoid evaporation of any of the 
Treatment Group Male Female 
Unaffected Vehicle Control 5 4 
Affected Vehicle Control 4 4 
Low Dose (10 mg/kg) CBD 4 4 
High Dose (25 mg/kg) CBD 4 4 
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vehicle components. One millilitre of this combined solution was then pipetted into 
24-well plates. 
 
The preparation of CBD-jelly varied slightly and was prepared separately. The 
amount of the regular sugar-inclusive jelly was increased from 0.5 g to 1 g per 50 mL 
jelly. This was due to the discountenance of treated mice consuming the drug-jelly 
several days into the treatment period. Sugar-free jelly and additional gelatine 
quantities remained the same. Using the weights of the treated mice taken either the 
day before or morning of jelly preparation, CBD quantitaties were calculated (CBD 
information in Appendix C). The weight taken at this time was accountable for the 
administered dosage to the respective mice for the following week. From this, a 
weeks worth of jelly and gelatine solution was calculated. The respective quantity of 
CBD was dissolved in the olive oil alone using a vortex shaker (TALBOY, Standard 
Vortex), which took up to 20 minutes, before being added to the equivalent volumes 
of ethanol and TWEEN® 20. The amount of vehicle was calculated from the volume 
of jelly solution equivalent to 1.5 mL total per 50 mL of jelly. The Jelly solution was 
cooled entirely until it began to set. This is essential so the heat does not denature the 
CBD and alter the effect of the drug. Once the jelly solution was cooled, the drug-
vehicle solution was added. The solution was then added to 24-well plates labelled for 
each of the treated mice based on the respective dosage calculations, where two-days 
worth may be added to one single well. Jelly was then left to set and stored in a 4 °C 
fridge. (Example calculations for both high and low dose jelly formulations in 
Appendix E). 
 
2.3 Jelly Feeding and Conditioning 
Prior to the commencement of the treatment period, all mice needed to be conditioned 
to eating the jelly. This involved food-depriving mice overnight (for approximately 16 
hours) before introducing vehicle-containing jelly to the mouse’s cage on a petri dish 
(figure 2.1). The mice were left with the jelly for several hours to investigate and/or 
eat the jelly before returning the dry food. Most mice will eat the jelly, however in the 
case that a mouse did not eat the jelly, the conditioning process was repeated after a 
two-day period to avoid malnutrition to the mouse. The mice were then fed the same 
jelly daily for 3-5 days to ensure continued consumption. Once the mice were 
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conditioned to eat the jelly, they could be left with their dry food only for several 
weeks before the treatment period, and would continue to eat the jelly when it is 
given.  
 
At the commencement 
of the treatment period, 
mice were given their 
respective jelly dosages 
in the morning between 
9 a.m. and 10 a.m. A 
single well of jelly was 
cut in half and used over 
two days. The jelly was 
given to mice on a petri 
dish with their tag 
number written on it. After several hours, the mice were checked to ensure they had 
consumed their jelly. If they had, the petri dishes were removed from the cage and 
were either placed in an individual plastic zip-lock bag, or placed on top of the dry 
food tray. This was so the mouse could not reach in and potentially break and injure 
itself on the ridged plastic dish. The mice were then checked again in the evening and 
the above process was repeated for the remaining mice. In the rare case the mouse did 
not consume all of the jelly, the jelly was left overnight along with a couple pieces of 
dry food while the remainder was removed.  
 
2.4 Behavioural Assessment 
Behavioural assessments were performed on the 28th day (second to last) day of 
treatment. The mice were moved from their housing room to a separate room in the 
Behavioural Phenotying Unit (BPU) where they were left for at least 30 minutes to 
acclimatise to the new environment under 25% regular light and a sodium light. All 
behavioural assessments were video recorded by cameras attached to the ceiling of the 
room. Marble burying test was carried out followed by the elevated plus maze test. 
Beginning at least a week prior to behavioural assessments, all mice were handled for 
several minutes at a time, daily. This was done in order to make mice more 




comfortable being handled so to reduce stress to the animals, which may potentially 
alter the results of the assessments.  
 
2.4.1 Marble Burying 
Marble burying tests were conducted for each animal once for a period of 30 minutes. 
New cages were set up with extra bedding (at least 5 cm from bottom) in order to 
accommodate for digging and burying, before being smoothed over. Nine white glass 
marbles were placed in the middle of the cages in a grid pattern approximately 3 cm 
apart from each other. Three to four cages were positioned under the view of the 
cameras, with empty cages between where possible, and as much space between cages 
the cameras field of view would allow for. Mice were placed in the cages, after which 
time the stopwatch was commenced and a curtain was pulled to minimize outside 
stimuli. After 30 min the mice were removed from test cages and returned to their 
own.  
 
Analysis of marble burying tests involved counting the number of marbles, which had 
been covered by the bedding at 5 min intervals – i.e. 0 min, 5 min, 10 min, 15 min, 20 
min, 25 min and 30 min. A marble was considered unburied if the bedding covered 
less than roughly 25% of its surface. A marble was considered half buried (0.5) if its 
surface is 26 – 75% covered by bedding. A marble was considered buried if bedding 
covered over 75% of its surface.  
 
2.4.2 Elevated Plus Maze 
At least a one-hour latency period was left between marble burying test and elevated 
plus maze test. An elevated plus maze assessment was administered to each mouse 
once, for a period of five minutes. Similarly, to the marble burying tests, an elevated 
plus maze was positioned under cameras. The arms of the elevated plus maze were 
300 mm in length and 70 mm in width with the walls of the closed arms being 150 
mm in height. The structure was made of clouded transparent–white acrylic and was 
elevated 635 mm from the floor. The structure was thoroughly cleaned with ethanol 
prior to the introduction of the mice and between each test to destroy any scents, 
which may alter test results. Animals were introduced to the centre of the elevated 
	
30 
plus maze facing one of the closed arms (the same each time) and a stopwatch was 
started. After five minutes mice were immediately returned to their cages. 
 
The analysis of the elevated plus maze tests involved measuring the amount of time 
spent by the mice in the open arms, closed arms and in the centre of the maze. A 
mouse was considered to be in the open or closed arms when its full body (not 
including the tail) was in the arm and no part of it was in the centre. The frequency of 
arm changes was also counted. This was separated into the number of times a closed 
arm and an open arm was entered.  
 
2.5 Tissue Collection 
Euthanasia was achieved with an overdose of sodium pentobarbital (150 mg/kg). 
Immediately following euthanasia (ensuring mice were no longer moving and did not 
respond to touch), the mouse had its chest cavity carefully opened. A butterfly needle 
was inserted into the heart at the apex. A small snip was made using surgical scissors 
at the right atrium and the mouse was perfused with 20 mL of 0.9% saline solution. 
All equipment had been thoroughly washed and kept in 30% ethanol.  
 
The head was removed and the brain was carefully dissected out of the skull before 
being cut in half down the middle to separate hemispheres. The right hemisphere was 
placed in a sterile screw-top falcon tube and dropped into liquid nitrogen to freeze. 
These brains were stored in -80 °C freezer for other studies. The left hemisphere was 
immersed in approximately 10 mL of fresh 4% PFA in a sterile universal for 24 hours. 
After this incubation period, brains were floated in 30% sucrose solution for 
cryoprotection until the brains had sunk (usually 36-48 h). Each brain was 
individually fixed in a Peel-A-Way® embedding mould by freezing in Tissue-Tek® 
O.C.TTM (optimal cutting temperature) Compound using dry ice and isopropanol. The 
cryofixed brains were stored at -80 °C until sectioning.  
 
Serial coronal sections were taken at 50 μm thickness using a Research Cryostat Leica 
CM3050 (-20 °C). Each section was stored in 100 μL of cryoprotectant solution in a 
96-well plate. One brain typically required two 96- well plates. Plates were wrapped 




2.6 Immunolabelling  
Biotinylated immunolabelling for GFAP (Sigma-Aldrich, G3893), CD68 (Bio-Rad, 
MCA1957), DCX (Santa Cruz, SC8066) and nNOS (Santa Cruz, SC5302) was 
performed on 50 μm coronal sections from the left hemisphere on all animal samples.  
 
2.6.1 Tissue Preparation 
Plates were removed from the -20 °C freezer and left either in a 4 °C fridge overnight 
or on a bench at room temperature for at least one hour. Every 12th section (an entire 
column) was taken from each set of brain sections. This accounted for 16 sections 
from each brain at every 0.6 mm interval across the brains (schematic in Figure 2.2). 
This was the case for all sets of immunolabelling, with the exception of the DCX 
labelling, where only the first 8 sections from each row were collected. Appropriate 
sections were then removed using a small wet (with phosphate buffer saline) 
paintbrush in a scooping motion. All sections from each animal were distributed 
across three wells of a 24-well plate (six, five and five) containing 1 mL of PBS 
(phosphate buffer saline). All sections were then either washed overnight or three 
times consecutively by changing PBS and leaving on shaker (Major Science Funny 
Shaker). Endogenous peroxidase activity was then quenched using freshly prepared 
PBS-T (PBS containing 0.3% Triton X100) with 1% H2O2 for 30 minutes at room 
temperature. Following this, sections were washed twice using PBS.  
 
 
Figure 2.2 Schematic overview of sections taken and stored across a mouse brain 
where the lines represent section and the blue wells represent the respective positions 





2.6.2 Blocking and Antibodies  
Prior to the addition of the primary antibodies, sections were blocked using 300 μL of 
15% normal serum in PBS-T per well. Normal goat serum (NGS) was generally used 
except in the case of DCX labelling, where normal donkey serum (NDS) was used. 
This blocking was left on for 60 – 120 minutes on a shaker at room temperature. 
Blocking solution was then removed and sections were washed twice using PBS.  
 
 Primary antibody solution (500 μL) was added to each well. Primary antibody 
solution consisted of the appropriate primary antibody dilution (Table 2.1, column 2), 
3% NGS or NDS in PBS-T. Plates were put on shaker for up to 2 hours before being 
incubated in 4 °C fridge overnight.  
 
Following the incubation and removal of primary antibody solution, three washes of 
sections were carried out. Once sections were sufficiently washed, 500 μL secondary 
antibody solution was applied to each well. Secondary antibody solution consisted of 
a 1:1000 dilution of appropriate secondary antibody (seen in Table 2.2, column 3) and 
3% NGS or NDS in PBT-T. Solution was left to incubate at room temperature on the 
shaker for four hours before being removed and washing sections three times in 
preparation for DAB staining.  
 
 
Table 2.2 Summary of Antibodies used. All secondary antibodies were used at 1:1000 
dilution. Listed dilutions indicate dilutions used for primary antibody.  
 
Primary Antibody Dilution Used Secondary Antibody 
Mouse anti GFAP 
(Sigma-Aldrich, G3893) 
1:1000 
Goat anti Mouse Biotin 
(Sigma-Aldrich, B7264) 
Rat anti CD68 
(Bio-Rad, MCA1957) 
1:1000 
Goat anti Rat Biotin 
(Sigma-Aldrich, B7139) 
Goat anti DCX 
(Santa Cruz, SC8066) 
1:500 
Donkey anti Goat Biotin 
(Novus Biological, NB1206884) 
Mouse anti nNOS 
(Santa Cruz, SC5302) 
1:500 




2.6.3 DAB staining and Mounting  
Prior to DAB staining, 1 mL of Extra-Avidin-HRP (1:1000 dilution of Extra-Avidin 
in PBS-T) was added to each well and incubated at room temperature for two hours. 
Extra-Avidin was removed and sections were rinsed three times with PBS-T. DAB 
solution was prepared following the instructions included in Vector Laboratories 
ImmPACT® DAB Peroxidase (HRP) Kit. This involved adding 30 μL of Chromogen 
to every 1 mL of diluent. Immediately before the addition DAB solution to the 
sections, 6 μL of 30% H2O2 for every 20 mL of solution was added. 500 μL was 
added to each well and colour was left to develop (5 – 15 minutes). Once the colour 
was fully developed, DAB solution was removed from sections and ice-cold PBS was 
introduced to the sections to stop the reaction. PBS was then removed and sections 
were left in PB until mounting to avoid salt crystallisation.  
 
Sections were then mounted by floating in PB and gently pulling up a clean 
microscope slide using a small paintbrush. The sections were carefully positioned and 
orientated, no more than three across, and flattened to avoid folds. Sections were 
allowed to dry completely, either overnight or for at least 6 hours. Slides were then 
immersed in increasing concentrations of ethanol – 70% for 5 minutes, 80% for 5 
minutes, 90% for 10 minutes and 100% for 10 minutes. Following this, slides were 
immersed in xylene for 30 minutes. After removal from xylene, and before sections 
dried out, a line of DPX mountant was added to the centre of the slides and 40 – 60 
mm cover slips (dependant on the amount of sections on the slide) were carefully 
lowered onto the sections and gently pressed. Care was taken to ensure there were no 
air bubbles remaining underneath the cover slips. Slides were allowed to dry 
completely prior to imaging and excess mountant was carefully peeled off.  
 
2.7 Autofluroescence 
Similar to the tissue preparation of immunolabelling, plates were removed from the -
20 °C freezer and left either in a 4 °C fridge overnight or on a bench at room 
temperature for at least one hour. Every 12th section was taken from each set of brain 
sections. Appropriate sections were then removed using a small wet paintbrush in a 
scooping motion. All sections from each animal were distributed across three wells of 
a 24-well plate containing 1 mL of PB. All sections were then either washed 
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overnight or three times consecutively with PB. No further treatment was applied to 
the sections. Each section was mounted to a glass slide as in the immunolabelling 
however sections were not left to dry completely. When the surface liquid had 
evaporated, but the sections were still wet (so that after the introduction of mountant 
to the slide, the sections would not move and shift), slides were cover-slipped. 
Antifade buffer (around 200 μL) was applied to the slides in a line down the centre. 
40 – 60 mm cover slips (dependent on the amount of sections on the slide) were 
carefully lowered onto the slides and gently pressed to remove air bubbles. Excess 
antifade buffer was blotted from the surface of the slides. Soon after, so to not dry 
slides out, clear nail polish (Sally Hansen’s No Chip Top® Coat) was applied to the 
perimeter of the cover slip, avoiding covering the sections underneath the slips. Once 
that had dried completely, a second coat was applied.  
 
2.8 Imaging and Analysis 
Slides were imaged on a Cytation 5 (Biotek, Millennium Science) using Gen 5 
image+ 2.09 software. For the immunolabelled slides, the bright field function was 
used. For the autofluorescent slides, the green fluorescent protein function was used 
(Appendix E.). Individual images taken from the Cytation were taken and stitched 
together using Adobe® Photoshop® CS6 (Appendix E.). 
 
Complete section images were analysed for quantity of staining in ImageJ (Fiji). 
Areas of interest were the motor cortex and thalamus in the GFAP, CD68 and nNOS 
stained sections as well as the autofluorescent sections. The hippocampus only was 
analysed for DCX stained sections. All regions were identified using the Paxinos & 
Franklin Mouse Brain Atlas (2008). Percentage area covered by positively stained 
cells were recorded for GFAP, DCX and nNOS immunolabelled sections. The 
number of positively stained cells per 1002 μm was recorded for CD68 
immunolabedlled sections and autofluorescent sections. Both were found using the 
‘Analyse Particles’ function on ImageJ. This involved selecting the area of interest 
and adjusting the grey scale threshold to select only stained areas (Appendix E.). 
Positive cells in CD68 immunolabelled sections were found via a more complex 
stereology protocol on ImageJ. Variable depth of DAB background staining between 
CD68 stained brains rendered the previously described protocol inappropriate. This 
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process involved selecting and measuring the area of interest, laying a set-dimension 
grid on top of the section images, and counting positive cells in at least 10% of the 
grids. Counted grids were found via a random number generator. Care was taken to 
only count positive cells touching the top and left-hand side of the grids and positive 
cells touching the bottom or right-hand lines of the grids were excluded. From the 
counted cells, the approximate total positive cells were found (Appendix E.). 
 
2.9 Statistical Analysis 
All statistical processing was done using GraphPad Prism® 6.0e. For behavioural, 
immunohistochemical and autofluorescent data, means were found +/- the standard 
error of the mean (SEM). Data was processed as both male and female together as 
well as separated into individual data sets. For the all-inclusive data, a Kruskal-Wallis 
one-way analysis of variance with Dunn’s post-hoc analysis was used. For gender 
separated data a Mann-Whitney U-test was used. A difference was considered 





Chapter Three: Results 
In order to determine if the administration of cannabidiol to CLN6 mice has an affect 
on markers of NCL, Cln6nclf mice were treated with 25 mg/kg CBD, 10 mg/kg CBD or 
vechicle only for a four-week period. During the treatment period, mice were weighed 
daily for a week, then every week following that. Behavioural assessments consisting 
of a Marble Burying Test, where the number of marbles buried over time were 
counted, and an Elevated Plus Maze Test, where the time spent in each arm 
(open/closed) was measured as well as frequency of arm changes were administered 
on the second to last day of treatment. Following this, the animals were perfused and 
the left hemisphere of the brains were prepared for analysis. Fifty μm thick coronal 
brain slices were stained immunohistochemically for inflammatory markers GFAP, 
CD68 and nNOS, as well as neurogenesis marker DCX. Sections were also prepared 
for imaging of autofluorescent materials. All sections were imaged using a Cytation 5 
Cell Imaging Reader. Quantifications of staining and autofluorescence were 
performed using ImageJ software. 
 
3.1 Mouse Weights 
Figure 3.1 shows the weights of the mice over the course of the treatment period. At 
the beginning of the study, all mice weighed between 17.9 g and 27.8 g, with an 
average weight of 23.1 g. More specifically, male mice weighed between 18.7 g and 
27.8 g with an average weight of 26.1, and all female mice weighed between 17.9 g 
and 21.3 g with an average weight of 19.9 g. By the end of the study, prior to 
euthanasia, all mice weighed between 19.1 g and 29.8 g, with an average weight of 
24.7 g. More specifically, male mice weighed between 19.1 g and 29.8 g with an 
average weight of 26.1, and all female mice weighed between 19.8 g and 21.3 g with 
an average weight of 24.7 g. During treatment, all mice gained 0 g to 3.1 g, with an 
average of 1.6 g. These accounted for 100%, 117.6% and 114.1% weight from 
beginning of treatment. Female mice tended to gain more weight than males, with an 
average gain of 2.1 g or 108.6% (1.3 g to 3.1 g or 106.3% to 117.6%), to the male’s 




While there are some noticeable differences in the average weights between the 
treatment groups for both male and female animals (Figure 3.1, B and C), these 
differences are consistent for the beginning of the treatment period.  
 
Figure 3.1 Weights of mice throughout treatment period. Mice were weight every day 
for one week, and once a week following that. A) Each animal’s weights, red data 
lines represent female mice and blue data lines represent male mice. B) Average male 
mice weights over time, C) Average female weights over time, Blue = -/+ vehicle only 
control, red = -/- vehicle only control, yellow = -/- 10 mg/kg CBD, green = -/- 25 





3.2 Behavioural Assessments 
3.2.1 Elevated Plus Maze 
Figure 3.2. displays results of the amount of time spent by animals in each arm of the 
elevated plus maze. Graph A shows results of both male and female mice grouped 
together. For time spent in the closed arms, the 25 mg/kg high dose treated group 
spent the most time in the closed arm (172 +/- 9.5 seconds), followed by the affected 
control group (Vehicle -/-, 167 +/- 8.3 seconds), unaffected control group (Vehicle +/-
, 145 +/- 18.3 seconds) and the 10 mg/kg low dose treatment group spent the least 
amount of time in the closed arms (133 +/- 13.8). As there is only around 38 seconds 
variation between all groups, there is no significant difference. Not unexpectedly, the 
exact opposite trend is true for the amount of time spent in the open arms by each 
group, with the 10 mg/kg low dose treated group spending the most time (132 +/- 17.0 
seconds), followed by unaffected control group (86.413 +/- 22.2 seconds), affected 
control group (70 +/- 9.4 seconds) and finally, 25 mg/kg high dose treated group (68 
+/- 10.2 seconds). There is, again, no significant difference between any groups.  
 
Figure 3.2 section B shows the amount of time spent by male mice only (right figure) 
and female mice only (left figure) in each arm of the elevated plus maze, to determine 
if the is a gender difference. The male results show a very similar pattern as 
previously mentioned. The 25 mg/kg high dose treated group spent the most amount 
of time in the closed arms (189 +/- 4.9 seconds) and least amount of time in open 
arms (49 +/- 8.5 seconds). 10 mg/kg low dose treated group spent the least amount of 
time in the closed arm (139 +/- 28.7 seconds) and most amount of time in the open 
arms (123 +/- 35.3 seconds). The female only results show that the affected control 
group spent the most amount of time in the closed arms (178 +/- 12.1 seconds) and 
the least amount of time in the open arms (62 +/- 18.9 seconds). These were both 
significantly different from the time spent by 10 mg/kg low dose treated group in both 
the open arms (142 +/- 6.1 seconds) and closed arms (128 +/- 6.2 seconds), p = 
0.0286. Both the unaffected control group and 25 mg/kg high dose treated group spent 
a similar amount of time in the open and closed arms (unaffected control, open arms – 
101 +/- 23.6 and closed arms – 137 +/- 25.0, and 25 mg/kg high dose control, open 





3.2 Elevated plus maze behavioural assessment. Average time spent in each arm 
(seconds) stacked. Male and female affected and unaffected mice were treated with 
vehicle and/or CBD for 4 weeks. A) All animals. B) Male mice only. C) Female mice 
only. White area represents time spent in open arms, grey area represents time spent 
in the centre or between arms and black area represents time spent in the closed 
arms. Data shown as mean +/- SEM, n= 4-5.  
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3.2.2 Elevated Plus Maze (Frequency Arm Changes) 
Figure 3.3 shows the results from the average frequency of arm changes by mice in 
the elevated plus maze. Figure 3.3, A shows both male and female mice grouped 
together. The unaffected control group made the most arm changes (25.5 +/- 0.945), 
and the most changes into a closed arm, and second most into an open arm (17.0 +/- 
0.926 and 8.5 +/- 0.906, respectively). 25 mg/kg high dose treated group made the 
second highest number of arm changes (24.6 +/- 2.179), consisting of the highest 
number of changes into an open arm, and lowest amount into a closed arm (10.0 +/- 
0.926, and 11.0 +/- 1.720, respectively). Both the 10 mg/kg low dose treatment group 
and the unaffected control group have a similar number in arm changes (21.0 +/- 
1.800 and 20.4 +/- 2.174, respectively), with similar proportions of open to closed 
arm changes (25 mg/kg high dose treatment group – 16.5 +/- 1.570 to closed and 8.1 
+/- 1.231 open. Un affected control group 12.1 +/- 1.006 closed and 8.3 +/- 2.392 
open). There is a significantly larger number of arm changes into a closed arm by the 
25 mg/kg high dose treated group than both the 10 mg/kg low dose treatment group (p 
= 0.0178) and the unaffected control group (p = 0.0025). There are no significant 
differences in the number of changes into an open arm. 
 
Figure 3.3, B shows the frequency of arm changes into both open and closed by male 
only, and female only. For the male only mice, affected control group had the highest 
number of arm changes (24.3 +/- 0.629), followed by 25 mg/kg high dose treatment 
group (21.8 +/- 1.601), unaffected control group (20.8 +/- 3.639) and 10 mg/kg low 
dose treatment group (20.0 +/- 3.00). The female only groups, the 25 mg/kg high dose 
treatment group had the highest number of arm changes (27.5 +/- 3.753), followed by 
affected control group (26.8 +/- 1.652), 10 mg/kg low dose treated group (22.0 +/- 
2.483) and unaffected control group (20.0 +/- 2.483). There are no significant 
differences.  
 
Taken together, the phenotype of the mice and the treatment given to the mice 
apparels to have no meaningful affect on the amount of time which they spend in 





3.3 Elevated plus maze behavioural assessment. Average frequency of arm changes. 
Male and female affected and unaffected mice were treated with vehicle and/or CBD 
for 4 weeks. A) All animals. B) Male mice only. C) Female mice only. White area 
represents number of times an open arm was entered and black area represents 





3.2.3 Marble Burying 
Figure 3.4 shows results from the marble burying assessment. For all mice (Figure 
3,4, A), at the end of the 30-minute observation period, the group on average with the 
most marble buried (i.e. the least marble visible) was the 10 mg/kg low dose treatment 
group (4.4 +/- 0.671 visible). This is followed by the 25 mg/kg high dose treatment 
group (4.9 +/- 0.766 visible), then the affected treatment group (6.5 +/- 0.802 visible), 
and finally the unaffected control group (7.9 +/- 0.661 visible). The unaffected control 
group had significantly lower marbles buried than both the treatment groups (25 
mg/kg high dose - p = 0.0164, 10 mg/kg low dose – p = 0.0384).  
 
When splitting the data into male and female (Figure 3.4, B), there is slight variability 
between sexes. For the male only data, both unaffected and affected control groups 
had a very similar number of marbles buried (6.6 +/- 1.246 visible and 7.3 +/- 1.127 
visible, respectively). Both treatment groups had buried more marbles by the end of 
the treatment period, with the 25 mg/kg high dose treatment group having only 4.3 +/- 
0.968 visible, and the 10 mg/kg low dose treatment group having 4.3 +/- 0.968 
visible. Although lower, there is not significance between either unaffected or 
affected control groups. This pattern was not carried through in female mice. The 
unaffected control group appeared to have very little interest in burying marbles, with 
all marbles still visible for all mice (9.0 +/- 0.000 visible). This was not the case for 
the affected control mice, who had a similar number of marbles buried as both the 25 
mg/kg high dose treatment group and 10 mg/kg low dose treatment group (5.8 +/- 
1.164 visible, 4.6 +/- 0.625 visible and 5.5 +/- 0.652 visible, respectively). Although 
all similarly low, only the 25 mg/kg high dose treatment group significantly buried 
more marbles then the unaffected control group (p = 0.0286).  
 
The unaffected control group appears to have no interest in burying marbles. The 
male affected control mice also appear to have little interest in burying marbles, while 
the females do. All treated mice, both high dose (25 mg/kg) and low dose (10 mg/kg) 





3.4 Marble burying behavioural assessment. Average number of marbles unburied 
over time (minutes). Male and female affected and unaffected mice were treated with 
vehicle and/or CBD for 4 weeks. A) All animals. B) Male mice only. C) Female mice 
only. Red data lines represent unaffected vehicle control group, blue data lines 
represent affected vehicle control group, yellow data lines represent low dose (10 
mg/kg) treatment group and green data lines represents high dose (25 mg/kg) 






3.3 Immunohistochemistry  
	
3.3.1 GFAP 
3.3.1.1 GFAP Staining of the Motor Cortex 
Figure 3.5 shows GFAP immunohistochemical staining of the motor cortex. Section 
A shows that there is a visibly lower level of staining in the unaffected control group 
compared to the affected control group, 10 mg/kg low dose treatment groups and 25 
mg/kg high dose treatment groups. This is quantified in all mice (male and female) in 
graph B, where the average percentage positive staining in the unaffected control 
group is 7.193 +/- 0.570. This is significantly more staining than affected control 
group (14.780 +/- 1.149 % stained), and 25 mg/kg high dose treatment group (14.191 
+/- 1.596 % stained), with p of 0.003 and 0.0017 respectively. 10 mg/kg low dose 
treatment group had a non-significantly higher (with respect to the unaffected control) 
percentage staining of 11.060 +/- 0.574 % stained. 
 
Similar patterns in staining were seen with male and female only data (figure 3.5, C). 
In male mice, there was a low level of staining in unaffected control mice (7.310 +/- 
0.836 % stained). This was significantly lower than staining in the affected control 
group (15.883 +/- 1.144 % stained), 10 mg/kg low dose treatment group (11.320 +/- 
0.931 % stained), and 25 mg/kg high dose treatment group (12.727 +/- 0.282 % 
stained) with p=values of 0.0159, 0.0357 and 0.0159 respectively. In female only 
data, there was a significantly lower percentage staining in the unaffected control 
group (7.048 +/- 0.887 % stained) than the affected control group (13.676 +/- 2.010 % 
stained), with a p of 0.0286. Although the highest average level of percentage staining 
was found in the 10 mg/kg low dose treatment group (16.144 +/- 5.785 % stained), it 
was not significantly higher than any other group. This is due to the high variability in 
staining levels. The 25 mg/kg high dose treatment group also had a higher percentage 
staining than unaffected control (10.699 +/- 0.667 % stained), but this difference was 




3.5 GFAP immunohistochemical staining of motor cortex. Male and female affected 
and unaffected mice were treated with vehicle and/or CBD for 4 weeks. A) Bright 
field images of staining, taken on Cytation5. B) Quantified staining as percentage 
area, all animals C) Quantified staining as percentage area, separated into males 
(left) and females (right). n = Unaffected vehicle control group, g = affected 
vehicle control group, ▼ = low dose (10 mg/kg) CBD treated group and ▲ = high 
dose (25 mg/kg) CBD treated group. Data shown as mean +/- SEM, n= 2-9.  
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3.1.2 GFAP Staining of the Thalamus  
Staining of GFAP in the thalamus was also observed and shown in Figure 3.6. Like 
the raw staining images in the motor cortex (figure 3.5, A), there is a visibly lower 
amount of staining seen in the unaffected control group than the affected control 
group, 10 mg/kg low dose treatment group and 25 mg/kg high dose treatment group 
(Figure 3.6, A). This is quantified in section B of figure 3.6. The staining seen in the 
unaffected control group is 3.996 +/- 0.471 percentage stained. This is significantly 
lower then the affected control group (15.655 +/- 2.426 % stained), the 10 mg/kg low 
dose treatment group (14.489 +/- 2.307 % stained) and the 25 mg/kg high dose 
treatment group (16.470 +/- 1.471 % stained) with p of 0.0036, 0.0017 and 0.0251 
respectively.  
 
The sex-separated data also follow a similar trend (Figure 3.6, C). For the male only 
data, the unaffected control group also has the lowest level of staining (4.483 +/- 
0.593 % stained). Although the remaining groups each have large standard error of 
the means, the unaffected control group staining is significantly lower than the 
unaffected control group (20.078 +/- 3.072 % stained), the 10 mg/kg low dose 
treatment group (14.641 +/- 3.167 % stained) and the 25 mg/kg high dose treatment 
group (17.043 +/- 2.084 % stained), with p of 0.0159, 0.0357 and 0.0159 respectively. 
In the females, the unaffected control group also has a low level of staining (3.388 +/- 
0.723 % stained). This is significantly lower than the affected control group (11.233 
+/- 2.232 % stained), with a p of 0.0286. The 10 mg/kg low dose treatment group 
(14.262 +/- 4.799 % stained) and 25 mg/kg high dose treatment group (15.706 +/- 
2.440 % stained), which have sample sizes of 2 and 3 respectively are however, are 
not significantly greater.  
 
In summary, the GFAP results show that there is significantly more GFAP present in 
the affected control group compared to the unaffected control group in both the motor 
cortex and the thalamus. This too is the case for the treatment groups in the thalamus 
in most cases, except for the thalamus and cortex of the females only (likely due to 
low n numbers) and the motor cortex staining for the low dose treatment group, where 




3.6 GFAP immunohistochemical staining of thalamus. Male and female affected and 
unaffected mice were treated with vehicle and/or CBD for 4 weeks. A) Bright field 
images of staining, taken on Cytation5. B) Quantified staining as percentage area, all 
animals C) Quantified staining as percentage area, separated into males (left) and 
females (right). n = Unaffected vehicle control group, g = affected vehicle control 
group, ▼ = low dose (10 mg/kg) CBD treated group and ▲ = high dose (25 mg/kg) 




3.3.2.1 CD68 Staining of Motor Cortex 
Figure 3.7 shows the results from CD68 staining of the motor cortex. Similar to the 
GFAP staining, there is a visually lower level of staining in the raw images of staining 
in the unaffected control group than the affected control group, the 10 mg/kg low dose 
treatment group and the 25 mg/kg high dose treatment group (figure 3.7, A). This 
tread is also shown in the quantification of staining in Figure 3.7 B. The unaffected 
control group has a significantly lower level of staining (4.420 +/- 0.399 positive 
cells/1002 μm) than the affected control group (6.751 +/- 0.344 positive cells/1002 
μm) and the 25 mg/kg high dose treatment group (6.114 +/- 0.487 positive cells/1002 
μm) with p of 0.0054 and 0.0428 respectively. The 10 mg/kg low dose treatment 
group also has a higher level CD68 staining (5.472 +/- 0.406 positive cells/1002 μm), 
although has no significant difference.  
 
For the male only data (Figure 3.7, C) the unaffected control group has a low level of 
staining (3.499 +/- 0.098 positive cells/1002 μm). This was significantly lower than 
the affected control group (6.087 +/- 0.351 positive cells/1002 μm) and the 10 mg/kg 
low dose treatment group (5.790 +/- 0.279 positive cells/1002 μm) both with p of 
0.0159. While the 25 mg/kg high dose treatment group also had a higher level of 
staining (5.531 +/- 0.903 positive cells/1002 μm), there was a large variance within the 
group as seen by the large standard error of the mean bars. Analogously, the female 
mice also had a low level of CD68 staining in the unaffected control group (5.571 +/- 
0.377 positive cells/1002 μm). This is significantly lower than the affected control 
group (7.416 +/- 0.365 positive cells/1002 μm) with a p- of 0.0286. Both the 10 mg/kg 
low dose and 25 mg/kg high dose treatment groups have similar, but slightly higher 
averages than the unaffected control group (5.913 +/- 0.323 positive cells/1002 μm 
and 6.698 +/- 0.258 positive cells/1002 μm respectively). These differences are not 






3.7 CD68 immunohistochemical staining of motor cortex. Male and female affected 
and unaffected mice were treated with vehicle and/or CBD for 4 weeks. A) Bright 
field images of staining, taken on Cytation5. B) Quantified staining as number of 
positive cells per 1002 μm, all animals C) Quantified staining as number of positive 
cells per 1002 μm, separated into males (left) and females (right). n = Unaffected 
vehicle control group, g = affected vehicle control group, ▼ = low dose (10 mg/kg) 
CBD treated group and ▲ = high dose (25 mg/kg) CBD treated group. Data shown 
as mean +/- SEM, n= 3-5.   
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3.3.2.2 CD68 Staining of Thalamus  
CD68 staining of the thalamus is shown in Figure 3.8. There is a visibly lower level of 
staining in the unaffected control tissue than the affected control, the 10 mg/kg low 
dose and the 25 mg/kg high dose in the raw images of CD68 thalamus staining 
(Figure 3.8, A). This is translated in the quantification of staining in Figure 3.8, B. 
The unaffected control group has only 1.315 +/- 0.245 positive cells/1002 μm. This is 
significantly lower than the affected control group (4.581 +/- 0.466 positive cells/1002 
μm), the 10 mg/kg low dose treatment group (4.622 +/- 0.310 positive cells/1002 μm) 
and the 25 mg/kg high dose treatment group (4.100 +/- 0.234 positive cells/1002 μm), 
with p of 0.0043, 0.0027 and 0.0147 respectively.  
 
The same trend is seen in the male-only data (Figure 3.8, C). The unaffected control 
group has only 0.745 +/- 0.245 positive cells/1002 μm. This is significantly lower than 
the affected control group (4.834 +/- 0.809 positive cells/1002 μm), the 10 mg/kg low 
dose treatment group (4.601 +/- 0.299 positive cells/1002 μm) and the 25 mg/kg high 
dose treatment group (4.791 +/- 0.350 positive cells/1002 μm), with p of 0.0159, 
0.0357 and 0.0159 respectively. Likewise, the female unaffected control group (2.029 
+/- 0.231 positive cells/1002 μm) and affected control group (4.238 +/- 0.563 positive 
cells/1002 μm) are significantly different (p = 0.0286. While both the female 10 mg/kg 
low dose treatment group (5.000 +/- 0 positive cells/1002 μm) and 25 mg/kg high dose 
treatment group (4.453 +/- 0.555) have higher levels of staining, there no are low n-
numbers and a large standard error of the mean in the 25 mg/kg high dose group and 
therefore no significance.  
 
The CD68 differs slightly between the motor cortex and the thalamus. In the cortex, 
there is a significantly higher level of staining in the affected control with respect to 
the unaffected control group. The treatment groups yielded similarly high levels of 
staining although, the low dose treatment group does not have a significantly higher 
level than the unaffected control group (this is also seen in the low dose treatment 
group in the male-only data). The CD68 staining of the thalamus shows there is 
significantly higher staining in the affected control group, high dose treatment group 




3.8 CD68 immunohistochemical staining of thalamus. Male and female affected and 
unaffected mice were treated with vehicle and/or CBD for 4 weeks. A) Bright field 
images of staining, taken on Cytation5. B) Quantified staining as percentage 
area/number of positive cells per 1002 μm, all animals C) Quantified staining as 
percentage area/number of positive cells per 1002 μm, separated into males (left) and 
females (right). n = Unaffected vehicle control group, g = affected vehicle control 
group, ▼ = low dose (10 mg/kg) CBD treated group and ▲ = high dose (25 mg/kg) 
CBD treated group. Data shown as mean +/- SEM, n= 9-1. 
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3.3.3 DCX Staining of Hippocampus 
Figure 3.9 shows the results from the hippocampal staining with DCX. The green box 
surrounding stained hippocampal cells indicates the measured stained area where, the 
red box surrounds the dark area of the hippocampus, which was excluded from 
quantification (Figure 3.9, A -/- Vehicle). As seen in Figure 3.9, A, there is a lower 
level of staining in the unaffected control group than the affected control group and 
the 25 mg/kg high dose treatment group, with the 10 mg/kg low dose staining falling 
in the middle. This is quantified in Figure 3.9, B. The unaffected control group as an 
average of 3.884 percentage tissue stained, with a tight standard error of the mean (+/- 
0.667). While the affected control group (10.946 +/- 2.413 % stained), 10 mg/kg low 
dose treatment group (9.358 +/- 2.285 % stained) and 25 mg/kg high dose treatment 
group (12.625 +/- 2.374 % stained) all have higher levels of staining, they also have 
large variability in percentage staining within the groups and therefore large standard 
error of the means. Only the 25 mg/kg high dose treatment group has a significant 
increase in staining (p = 0.0299).  
 
This high variability is predominantly seen in the affected male animals (Figure 3.9, 
B). The unaffected control group has a low level of staining with only 3.633 
percentage tissue stained and low variability (SEM = +/- 0.832). The affected control 
group (8.320 +/- 3.829 % stained), the 10 mg/kg low dose treated group (10.967 +/- 
6.534 % stained) and the 25 mg/kg high dose treatment group (12.225 +/- 3.099 % 
stained) however, have very high variability within each group. For this reason, there 
is no significant difference between and groups. The female animals only have large 
variability in the 25 mg/kg high dose control group (13.025 +/- 4.072 % stained). The 
unaffected control group has a low level of staining (4.1198 +/- 1.207 % stained). 
While there is also no significance in the increase, there is a higher level of DCX 
staining in the unaffected control group (14.449 +/- 0.841 % stained) and the 10 
mg/kg low dose treatment group (7.749 +/- 0.175 % stained).  
 
The variability within the affected animal groups (affected control, low dose treatment 





3.9 DCX immunohistochemical staining of hippocampus. Male and female affected 
and unaffected mice were treated with vehicle and/or CBD for 4 weeks. A) Bright 
field images of staining, taken on Cytation5. B) Quantified staining as percentage 
area, all animals C) Quantified staining as percentage area, separated into males 
(left) and females (right). n = Unaffected vehicle control group, g = affected 
vehicle control group, ▼ = low dose (10 mg/kg) CBD treated group and ▲ = high 




3.3.4.1 nNOS Staining of Motor Cortex  
Figure 3.10 shows results from motor cortex staining with nNOS. There is very little 
visible difference between any groups in the raw images (Figure 3.10, A). This is also 
the case in the quantified data (Figure 3.10, B). The affected control group (2.260 +/- 
0.446 % stained) has a lower level of staining than the unaffected control group 
(4.183 +/- 1.386 % stained). This difference, however, is not significant due to the 
large variability within the unaffected control group. The 10 mg/kg low dose 
treatment group (1.663 +/- 0.451 % stained) and the 25 mg/kg high dose treatment 
group (1.369 +/- 0.391 % stained) also have similarly low levels of staining as the 
unaffected control group.  
 
The male only data (Figure 3.10, C) show even smaller differences in staining, with 
the affected control group being 1.983 +/- 0.535 percentage stained, the unaffected 
control group 2.752 +/- 1.389 percentage stained, the 10 mg/kg low dose treatment 
group 1.315 +/- 0.725 percentage stained and the 25 mg/kg high dose treatment group 
0.982 +/- 0.316 % stained. The female data shows similar levels of staining in the 
affected control group (2.606 +/- 0.801 % stained), the 10 mg/kg low dose treatment 
group (2.185 +/- 0.008 % stained) and the 25 mg/kg high dose treatment group (1.757 
+/- 0.717 % stained). The affected control group (5.615 +/- 2.373 % stained) has a 
non-significantly higher level of staining and very high variability of staining within 




3.10 nNOS immunohistochemical staining of motor cortex. Male and female affected 
and unaffected mice were treated with vehicle and/or CBD for 4 weeks. A) Bright 
field images of staining, taken on Cytation5. B) Quantified staining as percentage 
area, all animals C) Quantified staining as percentage area, separated into males 
(left) and females (right). n = Unaffected vehicle control group, g = affected 
vehicle control group, ▼ = low dose (10 mg/kg) CBD treated group and ▲ = high 
dose (25 mg/kg) CBD treated group. Data shown as mean +/- SEM, n= 2-9. 
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3.3.4.2 nNOS Staining of Thalamus  
Figure 3.11 shows the results of nNOS immunostaining of the thalamus. Unlike the 
cortex staining (Figure 3.10, A), there is a more obvious visual difference in staining 
between the affected and unaffected control groups in the raw images (Figure 3.11, 
A). This is, again, translated into the quantified staining data (Figure 3.11, B), where 
the affected control group (1.510 +/- 0.393 % stained) has significantly lower staining 
than the unaffected control group (4.444 +/- 0.436 % stained) with a p of 0.002. The 
10 mg/kg low dose treatment group also has a higher level of staining (2.982 +/- 
0.317 % stained) but the increase is insignificant. Likewise, the 25 mg/kg high dose 
treatment group has a slightly higher level of staining (2.562 +/- 0.500 % stained) but 
is also insignificant.  
 
Similar to this, the male data also has a significant difference between the affected 
control group (1.923 +/- 0.632 % stained) and the unaffected control group (4.345 +/- 
0.452 % stained) with a p of 0.0317. Both the 10 mg/kg low dose treatment group and 
the 25 mg/kg high dose treatment group are also higher than the unaffected control 
group, but the difference is, again, insignificant (averages of 3.504 +/- 0.681 % 
stained and 2.741 +/- 0.182 % stained respectively). The female data has lower 
variability between the groups, and has no significant differences, where the affected 
control group is 0.971 +/- 0.306 percentage stained, the unaffected control group is 
4.643 +/- 1.250 percentage stained, the 10 mg/kg low dose treatment group is 1.621 
+/- 0.338 percentage stained and the 25 mg/kg high dose treatment group 3.143 +/- 
0.541 percentage stained. 
 
The nNOS staining data of the motor cortex shows that there is a significantly higher 
level of staining in the affected control group with respect to the unaffected control 
group, low dose treatment group and high dose treatment group. This trend is also 
seen in the male only data, however is not seen in the female data due to low sample 
numbers. The staining of the thalamus shows greater variability within the groups. For 
this reason, there is only a significant difference between the unaffected and affected 
control groups. The treatment groups however do show a reduction in staining with 




3.10 nNOS immunohistochemical staining of thalamus. Male and female affected and 
unaffected mice were treated with vehicle and/or CBD for 4 weeks. A) Bright field 
images of staining, taken on Cytation5. B) Quantified staining as percentage area, all 
animals C) Quantified staining as percentage area, separated into males (left) and 
females (right). n = Unaffected vehicle control group, g = affected vehicle control 
group, ▼ = low dose (10 mg/kg) CBD treated group and ▲ = high dose (25 mg/kg) 





3.4.1 Autofluorescent Imaging of Motor Cortex  
Figure 3.12 shows the results from the autofluorescent imaging of the motor cortex. 
From the raw images in Figure 3.12, A, it evident there is little to no fluorescent 
particles in the unaffected control group, and the affected control group, 10 mg/kg 
high dose group and the 10 mg/kg low dose group have visibly high amounts of 
fluorescent particles. This is quantified in Figure 3.12, B, where the affected control 
group (0.026 +/- 0.012 positive cells/1002 μm) has significantly lower amounts of 
fluorescent cells than the unaffected control group (0.413 +/- 0.082 positive cells/1002 
μm), the 10 mg/kg low dose treatment group (0.49 +/- 0.081 positive cells/1002 μm) 
and the 25 mg/kg high dose treatment group (0.357 +/- 0.018 positive cells/1002 μm) 
with p of 0.0083, 0.0004 and 0.0062 respectively.  
 
Both the male and female only data has the same trend (Figure 3.12, C). for the male 
data, the affected control group (0.026 +/- 0.015 positive cells/1002 μm) has 
significantly lower fluorescence then the unaffected control group (0.323 +/- 0.025 
positive cells/1002 μm), the 10 mg/kg low dose treatment group (0.378 +/- 0.144 
positive cells/1002 μm) and the 25 mg/kg high dose treatment group (0.339 +/- 0.021 
positive cells/1002 μm) with p of 0.0159, 0.0357 and 0.0159. For the female data, the 
affected control group (0.026 +/- 0.021 positive cells/1002 μm) again, has 
significantly lower autofluorescence than the unaffected control group (0.502 +/- 
0.160 positive cells/1002 μm), the 10 mg/kg low dose treatment group (0.374 +/- 0.03 
positive cells/1002 μm) and the 25 mg/kg high dose treatment group (0.574 +/- 0.083 




3.12 Autofluorescent imaging of motor cortex. Male and female affected and 
unaffected mice were treated with vehicle and/or CBD for 4 weeks. A) GFP images of 
50 μm brain sections, taken on Cytation5. B) Quantified staining as number of 
positive cells per 1002 μm, all animals C) Quantified staining as number of positive 
cells per 1002 μm, separated into males (left) and females (right). n = Unaffected 
vehicle control group, g = affected vehicle control group, ▼ = low dose (10 mg/kg) 
CBD treated group and ▲ = high dose (25 mg/kg) CBD treated group. Data shown 
as mean +/- SEM, n= 3-9.  
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3.4.2 Autofluorescent Imaging of Thalamus  
Figure 3.13 shows the results from the autofluorescent imaging of the thalamus. As 
for the motor cortex imaging, the raw images in Figure 3.13, A, shows there is little to 
no fluorescent particles in the unaffected control group, and the affected control 
group, 10 mg/kg high dose group and the 10 mg/kg low dose group have visibly high 
amounts of fluorescent particles. Also, similar to the motor cortex imaging, the 
quantified data (Figure 3.13, B) shows the affected control group (0.002 +/- 0.001 
positive cells/1002 μm) has significantly lower fluorescent particles than the 
unaffected control group (0.614 +/- 0.0610 positive cells/1002 μm), the 10 mg/kg low 
dose treatment group (0.752 +/- 0.122 positive cells/1002 μm), the 25 mg/kg high dose 
treatment group (0.599 +/- 0.050 positive cells/1002 μm) with p of 0.0052, 0.0017 and 
0.0064 respectively.  
 
Once again, the male and female data separately have the same trend in data (Figure 
3.13, C). For the males, the affected control group (0.002 +/- 0.0089 positive 
cells/1002 μm) has significantly less autofluorescence than the unaffected control 
group (0.621 +/- 0.103 positive cells/1002 μm), the 10 mg/kg low dose treatment 
group (0.635 +/- 0.126 positive cells/1002 μm) and the 25 mg/kg high dose treatment 
group (0.648 +/- 0.097 positive cells/1002 μm) with p of 0.0159, 0.0357 and 0.0159 
respectively. For the female data, the affected control group (0.027 +/- 0.022 positive 
cells/1002 μm) also has significantly lower autofluorescence than the unaffected 
control group (0.607 +/- 0.080 positive cells/1002 μm) and he 25 mg/kg high dose 
treatment group (0.549 +/- 0.029 positive cells/1002 μm) with p of 0.0286 and 0.0286 
respectively. While the10 mg/kg low dose treatment group also has a higher level of 
autofluorescence than the unaffected control group (0.926 +/- 0.224 positive 
cells/1002 μm), the difference is insignificant as the n number is low and the data is 
varied within the group.  
 
In both the motor cortex and thalamus there is almost no autofluorescence in the 
tissue of the unaffected control group. All other groups show very similar levels of 
autofluorescence and there is no difference between the affected control group and 
either the low dose treatment group or high dose treatment group.  




3.13 Autofluorescent imaging of thalamus. Male and female affected and unaffected 
mice were treated with vehicle and/or CBD for 4 weeks. A) GFP images of 50 μm 
brain sections, taken on Cytation5. B) Quantified staining as number of positive cells 
per 1002 μm, all animals C) Quantified staining as number of positive cells per 1002 
μm, separated into males (left) and females (right). n = Unaffected vehicle control 
group, g = affected vehicle control group, ▼ = low dose (10 mg/kg) CBD treated 
group and ▲ = high dose (25 mg/kg) CBD treated group. Data shown as mean +/- 
SEM, n= 2-5. 
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These results show that, all mice, regardless of treatment, maintained a healthy 
weight. The elevated plus maze assessment yielded no meaning full difference 
between groups, while the marble burying assessment showed that the affected mice, 
dependant on gender, as well as all treated mice buried more marbles. For brain 
section images, the GFAP, CD68 and nNOS (thalamus only) staining as well as 
autofluorescence showed significant differences between the affected and unaffected 
control groups. In the CD68 staining and autofluorescence there is also a significant 
difference between the unaffected control and both the treated groups. In other cases, 
as seen in GFAP and nNOS (thalamus only), the treated groups fall somewhere 
between the controls groups, and have no significant differences. Finally, the DCX 
stained images show high variability within groups and therefore it is difficult to 




Chapter Four: Discussion  
	
4.1 Summary 
The aim of this investigation was to observe the effects of cannabidiol treatment on 
Cln6nclf mice. While some behavioural and immunohistohemical staining yielded 
significant differences between the affected and unaffected vehicle control groups, the 
treatment groups produced similar results as the affected control group. In some cases, 
the treatment groups gave results toward the unaffected control groups, but were 
neither significantly different from the unaffected control group or the affected 
control group. The dosage, 10 mg/kg or 25 mg/kg appeared to have little to no effect 
on the results. There is no evidence that the treatment of CBD on affected Cln6nclf 
mice Batten mice at the age 1 – 1.5 months for a period of 4 weeks has any significant 
affected on disease progression. The use of voluntary oral dosing via the medium of a 
sweet raspberry jelly, however, provided an easy, non-invasive and effective method 
of oral drug administration.  
 
4.2 Methodology 
Many factors were considered in the decisions made in the methodology throughout 
this study. This included the number of animals used and treatments given to them, 
the dosages used and the method of administration, the behavioural assessments 
carried out, the choice of immunohistohemical labelling and the locations of interest 
as well as the specific proteins of interest.  
 
4.2.1 Animals and Dosing 
This study consisted for four different treatment groups. The first two were the 
unaffected control group and affected control groups, both of which received jelly 
containing the vehicle only. This was to give the treatment groups something to 
compare to, as well as account for any possible effect from the CBD vehicle. No 
unaffected treatment group was included in this study. This was primarily to keep 
animal numbers down, as well as for the reason that CBD would not be administered 
to a healthy individual, so the effect of CBD on a healthy mouse was not included in 
this investigation. The inclusion of such a group would principally benefit in the 
statistical analysis, therefore it would be more humane to work around this obstacle. 
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The remaining two groups consisted of a low dose treatment group (10 mg/kg) and a 
high dose treatment group (25 mg/kg). Each of the four groups contained four male 
Cln6nclf mice and four female Cln6nclf mice. This gave an appropriate total number of 
eight animals in each group, and allowed for the observation of potential differences 
in effect of treatment between the sexes.  
 
The dosage of 25 mg/kg CBD was selected as an appropriate oral dose from a review 
of literature. A 2000 study of CBD for arthritis in mice found 25 mg/kg to yield the 
optimum effect via intraperitoneal injection (IP) daily for 10 days (Malfait, et al., 
2000). The same study found that the oral administration and IP injection had similar 
effects. Another study found 15 – 30 mg/kg CBD administered orally was effective in 
decreasing interleukin (IL) -10 and IL-12 in mice (Sacerdote, et al., 2005). Again, the 
same effect was also stated to be found via IP injection. A third study of Alzheimer’s 
disease in mice found that an oral dose of 20 mg/kg CBD daily for 8 months 
prevented the social recognition deficit found in the disease, as well as a non-
significant decrease in IL-1b and TNF-a (Chen, et al., 2014). The second, low dosage 
of 10 mg/kg CBD was selected to observe if a similar effected could be found as the 
25 mg/kg, at a lower dosage. While there are few studies which use this low dose 
orally, one study did report the dose-dependent decrease of a pain-response from 10 
mg/kg – 60 mg/kg orally administered CBD (ED50 = 32.5, Chersher, et al., 1974). 
There are, however, many studies which have reported favourable results using 10 
mg/kg CBD via IP injection. These studies include inflammatory hypermotility 
(Capasso, et al., 2008), diabetic cardiomyopathy (Rajesh, et al., 2012), Colitis 
(Borrelli, et al., 2009) and cisplatin-induced nephrotoxicity (Pan, et al., 2009) in mice, 
as well as tolerance (Oviedo, et al., 1993), cognitive impairment relevant to 
neurodegenerative disorders (Fagherazzi, et al., 2012), pentylenetetrazole-induced 
generalised seizures (Jones, et al., 2012) and anxiety (El Batsh, et al., 2012) in rats. 
 
4.2.2 Voluntary Oral Dosing  
Voluntary oral dosing, as previously outlined, was used in this study for several 
reasons. First, oral dosing is the most common and most simple route of drug 
administration in humans. Secondly, and most importantly, voluntary oral dosing 
provides a method of drug administration where there is little to no risk of potentially 
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harming the mice both physically and psychologically. This is beneficial to both the 
welfare of the animals, as well as the researcher. The addition of a drug to a sweet 
tasting food both navigates the hurdle of administering a drug to the animal, it also 
gives the animal a tasty treat. This method of drug administration yielded no negative 
implications on the health of the mice (discussed in 4.3.1). While this particular study 
did not assess the potential differences in effect of voluntary oral dosing to other 
dosing methods, several other studies have reported the same therapeutic effected in 
oral dosed CBD and IP injected CBD (Malfait, et al., 2000; Sacerdote, et al., 2005). 
In addition to this, some studies have demonstrated the efficacy of the method 
compared to the classic oral administration method of oral gavage (Diogo, et al., 
2015; Kalliokoski, et al., 2011). All in all, the use of voluntary oral dosing in this 
study provided an effective and humane method of drug delivery.  
 
4.2.3 Behavioural Assessments 
Both elevated plus maze and marble burying tests were carried out on the mice. Both 
tests are employed to depict anxiety and/or obsessive-compulsive disorder (OCD) 
behaviours, and are classically used in the assessment of anxiolytic and anxiogenic 
drugs. In the elevated plus maze, the level of anxiety is measured by the amount of 
time spent by the animal in the closed arms of the maze and aversion of open spaces. 
This is based on the prey animal’s innate trait to retreat to closed spaces, away from 
the open space and view of potential prey, particularly when stressed. The test has 
been used extensively since its first description in 1985 (Pellow, et al., 1985) and has 
been validated behaviourally, physiologically, and pharmacologically (Walf & Frye, 
2007). Where an anxiolytic drug is administered, such as benzodiazepine, the animals 
will spend less time in the closed arms. When the drugs activity is inhibited, with 
benzodiazepine receptor inverse agonists, FG 7142 for example, the animals will 
spend more time in the closed arms (Pellow & File, 1986). The marble burying test is 
used to measure both anxiety and OCD. This test is based on the knowledge that mice 
and rats will bury a foreign object (harmful or not) in their bedding. There is 
somewhat more controversy over the interpretation of findings from a marble bury 
test than with the elevated plus maze (Thomas, et al., 2009). When an animal is 
placed in a cage or enclosure with marbles sitting on top of bedding, it will bury them. 
This action is seen to be related to anxiety or OCD, so when an anxiolytic or anti-
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compulsive drug is administered, this activity will reduce (Njung’e & Handley, 1991). 
The marble burying test is particularly sensitive to SSRIs (selective serotonin [5-HT] 
reuptake inhibitors) and benzodiazepines. While the direct aim of this study was not 
to observe the anxiolytic or anti-obsessive-compulsive action of CBD treatment on 
Cln6nclf mice, CBD is speculated to produce an anxiolytic effect as well as potentially 
even blocking the anxiogenic effect of Δ9-THC (Zuardi, et al., 1982). The tests were 
however, employed to observe the normal behaviour of an unaffected Cln6nclf 
compared to an affected, untreated Cln6nclf mouse, as well as the effect of the CBD 
treatment on affected Cln6nclfmice.  
 
4.2.4 Immunolabelling and Imaging 
The antibodies used in immunolabelling, as well as autofluorescent imaging, were 
used to analyse and quantify disease state. This was via inflammation, marked by 
GFAP, CD68 and nNOS, neurogenesis, marked by DCX, and the autofluorescent 
imaging as a direct measure of disease state. The area of interest for GFAP, CD68, 
nNOS and autofluorescent imaging was the motor cortex and the thalamus. The motor 
cortex region reflects the site of neuron loss in both humans and Cln6nclf and is the 
region responsible for motor coordination, vision memory and learning (Morgan, et 
al., 2013), this is also seen within the thalamus (Allendoerfer & Shatz, 1994). DCX 
staining was observed in the hippocampus only, as this is the primary site of adult 
neurogenesis (Kempermann, et al., 2015). GFAP is a class-III intermediate filament 
protein expressed by cells of the central nervous system, specifically astrocyte glial 
cells. The presence of such astrocytes is evidence of inflammation. Neuronal ceroid 
lipofuscinosis tissue has been shown to have an increase in the presence of GFAP 
compared to healthy tissue (Xu, et al., 2010; Yoritsune, et al., 2014). A reduction of 
the presence of GFAP on affected animals towards the level of unaffected animals 
would indicate a reduction in inflammation and may be indicative of disease 
progression. Similarly, the transmembrane glycoprotein CD68 is also a marker of 
inflammation. CD68 is present in lysosomes and endosomes of some blood cells and 
myocytes, and is a particularly good marker of macrophages and their derivatives 
including brain microglia (Holness, et al., 1993). Furthermore, there is evidence that 
CD68 could play a role in intercellular lysosomal metabolism (Holness, et al., 1993). 
Like GFAP, CD68 is increased with disease state (Seehafer, et al., 2011), and a 
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reduction in its expression toward the healthy animals would indicate a therapeutic 
effect (Holness, et al., 1993). nNOS is the neuronal form of nitric oxide synthase, 
found in the neuronal tissue both central and peripheral nervous systems, and in some 
skeletal muscle. The role of the NOS family enzymes is to catalyse the production of 
nitric oxide (NO) from L-arginine. nNOS in particular is involved in the development 
of the nervous system. It is likely very important in learning and memory as it has 
been shown to function as a retrograde neurotransmitter, important in long term 
potentiation (Paul & Ekambaram, 2011). While NO has an important role in 
vasodilation via its activation of soluble guanylate cyclase (which them forms cyclic-
GMP, which activates protein kinases G and causes the reuptake of Ca2+), earning it 
Science’s ‘Molecule of the year’ in 1992 (Moncada, et al., 1991; Koshland, 1992), 
NO is also a cellular signalling molecule and mediator and regulator of inflammatory 
responses (Korhonen, et al., 2005). It has been shown to mediate glutamate 
neurotoxicity (Dawson, et al., 1991), and its production via microglia and peripheral 
macrophages may contribute to secondary tissue damages and cell death in some 
forms of NCL (Nakanishi, et al., 2001). There is also evidence that NO also 
stimulates the expression of GFAP. NO utilizes the guanylate cyclase cGMP protein 
kinase G (PKG) pathway to increase the expression of GFAP, collectively 
contributing to the pathogenesis of neurodegenerative diseases (Brahmachari, et al., 
2006). It is unknown what the effect of NCL pathology has on nNOS levels. DCX is a 
microtubule-associated neuronal migration protein which is expressed by neuronal 
precursor cells and in immature neurons and a valuable marker of neurogenesis 
(Balthazart & Ball, 2105). Where there is neuronal damage as the result of injury or 
disease, deficits arise from the death of neurons, but also to some extent by the 
disruption of neurogenesis (Krathwohl & Kaiser, 2004a/b; Kaul, 2008). Microglial 
activation from disease has been shown to impair neurogenesis and contribute to 
pathogenesis (Monje, et al., 2003; Ekdahl, et al., 2003). The impact NCL disease state 
had on neurogenesis and DCX expression is not well established, in theory, an 
increase in neurogenesis implicates neuronal damage and therefore can gauge disease 
progression. However, an increase in neurogenesis may aid the slowing of disease 
progression, or give rise to appropriate target of treatment. Finally, the presence of 
autofluorescence is a direct indication of the extent of NCL disease pathogeny. A 
healthy individual will have little to no autofluorescent material present in the 
	
68 
neuronal cells where an affected individual will have a high level of autofluorescent 
material. The extent of autofluorescence relative to untreated tissue will show where a 
corrective or slowing therapeutic effect of a drug is present.  
 
4.3 Summary and Discussion of Results 
4.3.1 Mouse Weights 
The animals in this study were weighed every day for the first week of the treatment 
period, and then once a week for the remainder of the treatment period (Figure 3.1). 
This was in order to monitor if the administration of the drug to the animals was 
detrimental to their health (i.e. the animals were losing weight), and to observe if the 
daily consumption of a sweet jelly was making the animals gain weight and possibly 
interfere with the study. Figure 3.1 shows that all mice maintained a healthy weight 
throughout the study, comparable to the normal growth of a mouse (Gail & Kyle, 
1968) as well as other Cln6nclf mice (Morgan, et al., 2013). While the average weights 
of each group over time (Figure 3.1, B and C) show some differences in weights, 
these same differences are maintained from the start of the treatment period till the 
end of the treatment period. This data implies that for the treatment period of four 
weeks with both the jelly and the CBD, does not negatively impact the weight of the 
mice.  
 
4.3.2 Behavioural Assessments 
The elevated plus maze showed no difference in time spent in either the open or 
closed arms between the affected and unaffected control groups (Figure 3.2). This was 
also the case for the high dose treatment group, and only the low dose treatment group 
deviated slightly from this. The female low dose treatment group spent significantly 
more time in the open arm than the affected control group. The frequency of arm 
changes, again showed few differences. The data gathered from the marble burying 
test is perhaps more sensitive to behavioural differences than the elevated plus maze 
(Figure 3.3). Both male and female, high and low dose treated animals showed a 
higher number of marbles buried, indicating a higher level of anxiety or OCD. For the 
male mice, both the unaffected and affected control groups buried a low number of 
marbles, in the female groups, the unaffected control group buried no marbles, while 
the affected control group buried a similar amount to the treatment groups. It is 
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difficult to determine if the higher level of anxiety in these groups is due to the 
disease or the treatment. The difference between the genders may be a result of the 
female mice having a more servere disease course than the males, as seen in NCL 
patients (Cialone, et al., 2012). There is no data on Cln6nclfmice in the elevated plus 
maze, however, there is data on the effects CBD on mice in the elevated plus maze. A 
low dose (1 – 10 mg/kg) has been shown to have an anxiolytic effect, where the 
subjects spent more time in the open arms (Guimarães, et al., 1990; Guimarães, et al., 
1990). One of the studies used a higher CBD dose of 20 mg/kg, where the anxiolytic 
effect was reported to be no longer effective (Guimarães, et al., 1990). Marble 
burying has been shown to be similarly attenuated with CBD, including at higher 
doses (30 mg/kg and greater) (Casarotto, et al., 2010; Deiana, et al., 2012). This taken 
together with data showing the disease state induced stress (Zhou, et al., 2015), it is 
possible to say that the increase in marble burying is due to disease, and the treatment 
of CBD has no effect on it.  
 
4.3.3 GFAP Staining 
GFAP immunostaining of the motor cortex and thalamus yielded significantly more 
staining in the affected control group than in the unaffected control group (Figure 3.5 
and Figure 3.6). Overall in the motor cortex, there was also significantly higher 
staining in the high dose CBD treatment group, and both low and high dose CBD 
treated groups had significantly higher staining than the unaffected control in the 
thalamus. The low dose CBD treatment group yielded a higher level of GFAP staining 
than the unaffected control in the motor cortex, however was neither significantly 
higher than the unaffected control or significantly lower than the affected control 
group. This indicates that the 10 mg/kg CBD may have a minor effect on GFAP levels 
in Cln6nclf Batten mice (this was however not observed in the thalamus). Although it is 
not definitive due to the low female animal numbers, it is likely there is no varying 
affect in the presence of GFAP between males and females. The increase in GFAP 
with disease has previously been reported in Cln6nclf mice (Morgan, et al., 2013), as 
well as CLN6 sheep (Oswald, et al., 2005), other forms of NCL mice (Macauley, et 
al., 2011; Pontikis, et al., 2004) and dogs (Katz, et al., 2007). CBD has been shown to 
lower the amount of GFAP staining in several different applications. A topical 1% 
CBD cream as shown to have a neuroprotective function by the reduction of GFAP 
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and other inflammatory markers in a mouse model of experimental autoimmune 
encephalomyelitis. The cream was applied daily for 28 days, and almost entirely 
attenuated the effects of the disease (Giacoppo, et al., 2015). Another study shows 
that a IP injection of 2.5 mg/kg and 10 mg/kg CBD dose-dependently inhibited GFAP 
expression in a mouse model for Alzheimer’s disease neuroinflammation (Esposito, et 
al., 2007). IP injection has also been shown to be effective in reducing GFAP in 
cerebral ischemia (Hayakawa, et al., 2008). Furthermore, a connection has been made 
between the increasing data linking neuroinflammation to schizophrenia and the 
ability of CBD to produce an antipsychotic-like effect via its ability to reduce glial 
reactivity (Gomes, et al., 2015). It is possible that the period of treatment in the 
current study was not long enough to elicit an inhibitory effect on GFAP expression in 
Cln6nclf mice.  
 
4.3.4 CD68 Staining 
The findings from the CD68 immunostaining were very similar to that of the GFAP 
(Figure 3.7 and Figure 3.8). There was a significant increase in CD68 staining in the 
affected control group in both the motor cortex and thalamus with respect to the 
unaffected control group. Again, like in GFAP staining, there was also a significant 
increase in staining in the high dose CBD treatment group in the motor cortex, and a 
significant increase in both low and high dose CBD treatment groups in the thalamus 
compared to the respective unaffected control groups. Once again, like in GFAP 
staining, there was no significant difference in the motor cortex between the low dose 
treatment group and either the unaffected control group or the affected control group. 
This again, indicates that a prolonged CBD treatment at 10 mg/kg may have an effect 
on CD68 expression. There may be a slight increase in CD68 expression in the 
thalamus in females (both unaffected and affected). The increase in CD68 with 
disease has also been shown in motor cortex and thalamus of Cln6nclf mice to the age 
of 10 months (Morgan, et al., 2013). This same trend is seen in CLN3 model mice 
from the ages of 5 to 14 months (Pontikis, et al., 2004), and in CLN1, where an 
increase with disease in untreated animals is observed, and a subsequent decrease 
with enzyme replacement therapy (Lu, et al., 2015). An increase in CD68 in the motor 
cortex and thalamus has also been reported in progranulin-deficient mice, which 
present NCL-like pathology, from the age of 2.3 months (Tanaka, et al., 2014). There 
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is little information on the effect of CBD treatment on CD68 levels. One paper, 
however, reported that CD68 and other relevant proteins (such as CD13, CD29, 
CD37) involved in immune response had a decreased expression, while also 
upregulating others, such as CD109, CD151 and CD40, implicated in inhibiting the 
immune response (Libro, et al., 2016).  
 
4.3.5 DCX Staining 
The DCX was difficult to quantify due to the dark non-specific staining in the 
hippocampus (Figure 3.9, A – indicated by red box). This area was excluded from the 
quantification as much as possible, however may still impact the findings. While there 
is an increase in the DCX staining from the unaffected control group, to the affected 
control group as well as the low dose and high dose treatment groups, the difference 
was only significant in the high dose treatment group (Figure 3.9). This finding 
however should be taken with some reservations as there is a large standard error of 
the mean and large variability in staining within the group. This is also the case for 
the affected control group and the high dose CBD treatment group, where the 
averages are within 3% of the high dose treatment group, however do not yield any 
significance due to the high variability. On the other hand, the unaffected control 
group had low variability in staining within the group. It is possible that neurogenesis 
or at least the neurogenesis marker DCX levels fluctuate with disease, or that the age 
of onset is varied. While there is no information on the effects of NCL on adult 
neurogenesis, it is believed that several of the implicated proteins in other NCLs; 
CLN1, CLN2, CLN3 and CLN5 may be involved in the process (Fabritius, et al., 
2014; Minye, et al., 2016) Additionally, neurogenesis is altered in other 
neurodegenerative disorders; Parkinson’s disease, Alzheimer’s disease and 
Huntington’s disease despite the distinct pathological proteins accounting for the loss 
of different neural populations, the same alterations are observed across the diseases 
(Winner & Winkler, 2015). Furthermore, the locations of the altered neurogenesis, 
including the dentate gyrus of the hippocampus, imitate the early symptoms seen in 
the neurodegenerative diseases such as depression, anxiety and olfactory dysfunction 
and it is thought that the adult regenerative process might alter or alleviate symptoms 
so these diseases (Steiner, et al., 2006). CBD has been shown to enhance the 
expression of DCX and therefore neurogenesis. Single and repeated doses of 3 mg/kg 
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CBD both increased the expression of DCX (along with other neurogenesis markers) 
in the hippocampus and subventricular zone. Alternatively, at the higher dose of 30 
mg/kg this effect was attenuated (Schiavon, et al., 2016). A second study has shown 
that CBD increased DCX and neurogenesis without affecting learning and memory, 
while the opposite was true for THC, where learning was impacted without affecting 
neurogenesis (Wolf, et al., 2010). This indicates that the neurogenic effect of CBD is 
independent of the CB1 receptor. It is possible the effects of CBD on NCL will 
become clearer with a longer treatment period and/or larger animal group.  
 
4.3.6 nNOS Staining 
Like GFAP and CD68 immunostaining, there was a significant increase in nNOS 
staining in the affected control group compared to the unaffected control group in the 
thalamus (Figure 3.10). However, this was not the case for the motor cortex, where 
there was an increase, but due to high variability within the affected control group 
(Figure 3.11). Variability was a seen within both the affected control group and the 
other affected groups, this suggests that there is variability in the expression of nNOS 
between individuals, fluctuations in the expression, or some other factor influencing 
the expression. In the motor cortex, there was an insignificant increase in staining in 
the affected control group compared to the unaffected control group. Both the low 
dose and high dose treatment groups have a lower quantity of staining, where it 
appears to have been returned to the levels of the unaffected control group. As these 
changes were not significant, a therapeutic effect may not be reported, however the 
data suggests that with a larger experimental group, significance may be reached. This 
is somewhat supported by the thalamus staining data, where there is a significant 
increase in staining from the unaffected control group to the affected control group. 
While there is again a decrease in staining in both the low and high dose treatment 
groups (dose-dependently), the levels are not restored to unaffected control levels. 
This may be attained with prolonged treatment, or with a higher dosage of CBD. 
There appears to be no difference in nNOS staining between males and females, 
however it is difficult to tell because of the low female animal numbers. The effect on 
NCL diseases has on NOS is largely unknown. It has been observed that in CLN10, 
iNOS is increased and therefore cell death via apoptosis, where this cell death is then 
decreased with NOS-inhibitiors L-NAME and SMT (Koike, et al., 2003; Nakanishi, 
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et al., 2001). CLN3 on the other hand, has a decrease in nNOS due to its deficit 
arginine (the precursor for NOS) transportation (Ramirez-Montealegre & Pearce, 
2005; Chen, et al., 2008). While there are reports of investigation of iNOS and NCLs 
(Palmer, et al., 2015), nNOS has not been investigated. The interest in nNOS in this 
study, however, related to its expression following the treatment of CBD. CBD has 
been shown to attenuate NOSs in induced inflammation. CBD impaired iNOS in b-
amyloid induced neurinflammation (Esposito, et al., 2007) and in cisplatin-induced 
nephrotoxicity (Pan, et al., 2009). However, a 2007 study investigated the anti-
inflammatory properties of CBD on all three NOS forms in a neuropathic (sciatic 
nerve chronic constriction – nNOS and iNOS) and inflammatory pain models 
(complete Freund’s adjuvant implant injection – eNOS and iNOS). In the neuropathic 
pain, CBD had no effected on iNOS, but a minor effect on nNOS, and in the 
inflammatory pain model, CBD again, had no effect on iNOS but reduced eNOS 
(Costa, et al., 2007). This slight, and insignificant decrease in nNOS expression 
reported is similar to the effect observed here. The NOS staining provided interesting 
preliminary data, which may be investigated further with a larger group.  
 
4.3.7 Autofluorescence Imaging 
In both the motor cortex and the thalamus the unaffected control group had 
significantly less autofluorescent material than the affected control group, low dose 
treatment group and high dose treatment group (Figure 3.12 and Figure 3.13). This 
difference was slightly heightened in the thalamus compared to the motor cortex. As 
the unaffected control group consisted of healthy animals without any phenotype of 
Batten disease, there should be no autofluorescent particle, meaning there is no built 
up storage deposits. Any residual autofluorescence picked up in analysis is negligible 
and accountable to possible small bubbles or particles of dust in the images. While 
there is some larger variability within each of the affected groups, the daily treatment 
of CBD at both a low dose of 10 mg/kg and a high dose of 25 mg/kg for 4 weeks 
appears to have no effect on the presence of these autofluorescent storage materials. 
From this it can be concluded that the treatment of CBD has no corrective effect on 
the accumulation of these fluorescent storage lysosomal bodies. While there was a 
large number of these particles in the affected tissues, making it difficult to determine 
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a decrease in their production, there is also no evidence of preventative action of CBD 
against the formation of autofluorescent materials.  
 
4.4 Limitations  
There are a few limitations which apply to this study. First of all, the number of 
animals used. This was the first study of CBD by this lab, so it would be inappropriate 
to do a large-scale investigation without much preliminary information. This means 
that finding differences between treatment groups is more difficult and true 
modifications of behaviour or immunostaining may be masked by variations between 
individuals within the same treatment group. This limitation was also very apparent in 
the immunostaining of the female mice. When the cryostat sectioning machine in the 
lab broke, an alternate machine was used for some of the sectioning. This involved 
transporting the sections on dry ice to maintain a low temperature. However, the 
contact from the section plates to the dry ice (-78.5 °C) caused some of the sections to 
crack and therefore make them difficult, or in some cases impossible to use for 
immunostaining and imaging. Another limitation was the treatment period. Similar to 
the previous, it would be inappropriate do a long on-going investigation into the effect 
of CBD on CLN6 when the effect (if at all) is unknown. This study was also limited 
in the effects of the concentrations of CBD on CLN6. Only 10 mg/kg and 25 mg/kg 
CBD doses were used, therefore the effect at higher or lower doses is unknown. As 
previously mentioned, this study was limited in the fact there was no CBD control 
group (+/- Cln6 10 or 25 mg/kg CBD treatment control group). This would assist 
statistically and in deciphering if effects are due to the disease, the CBD treatment, or 
both. Finally, this investigation was limited in the sensitivity of immunohistochemical 
staining with DAB. Compared with fluorescent staining, DAB staining is more 
difficult to precisely define an area which is immunoreactive. This means that 
quantification can be difficult and less accurate than other forms of tags, such as a 
small air bubble or dust being picked up by ImageJ.  
 
4.5 Future Direction of Study 
For future studies in this area, it would be appropriate to observe the effects of CBD 
on Cln6nclf mice for a longer period of time, and/or with a larger animal group. Other 
markers of the disease could also be investigated such as iNOS and markers for 
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interneuronal loss parvalbumin and somatostatin. Both higher and lower oral doses of 
CBD may also be investigated to determine an optimum dose and the use of CBD in 
conjunction with other therapies. Other behavioural and physical tests should be 
investigated in treating Cln6nclf mice with CBD, such as rotor rod and water maze to 
observe the effects of the drug on the animals physically. Another interesting avenue 
for future investigation would be to see the difference therapeutically between CBD 
administered alone and CBD administered with THC. Finally, in terms of the 
methodology or treatment, other forms of anti-inflammatory drugs or compounds may 
be of specific interest to the treatment of NCLs due to the increase data linking it to 
disease progression.  
 
4.6 Conclusions  
In conclusion, while this investigation had yielded no evidence that CBD has a 
therapeutic effect on Cln6nclf mice, it has provided an indication that further 
investigation into the treatment may provide a therapeutic application. Furthermore, 
this investigation has provided further evidence of the effectiveness, convenience and 
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Appendix A: Materials and Suppliers 
 
Aeroplane Jelly Lite Raspberry 
Gelatine (Beef Origin), Flavours, Sweeteners (952,955,950), Acidity Regulator (297), 
Colours (122,133). 
Gregg's Raspberry Jelly 
Sugar, Gelatin (7%), Food Acid (330), Acidity Regulator (331), Flavour, Colour (122) 
Mckenzies Gelatine Powder 
Gelatine, Preservative (220) 
Pams Extra Light Olive Oil 
Olive oil (refined olive oil, extra-virgin olive oil) 
 
Mouse anti nNOS    Santa Cruz, SC5302 
Goat anti DCX   Santa Cruz, SC8066 
Mouse anti GFAP    Sigma-Aldrich, G3893 
Rat anti CD68    Bio-Rad, MCA1957 
Goat anti Mouse Biotin  Sigma-Aldrich, B7264 
Goat anti Rat Biotin    Sigma-Aldrich, B7139 
Donkey anti Goat Biotin  Novus Biological, NB1206884 
Goat anti Mouse Biotin  Sigma-Aldrich, B7264 
TWEEN® 20 (Polysorbate 20) Sigma-Aldrich, P9416 
Peel-A-Way® embedding mould Polysciences, Inc. 18646A-1 
Tissue-Tek® O.C.TTM  Sakura, 4583 
Normal Goat Serum   Sigma-Aldrich, NS02L 
Normal Donkey Serum  Sigma-Aldrich, 566460 
DPX Mountant   Sigma-Aldrich, 44581 
TritonTM X-100   Sigma-Aldrich, T8787 
ImmPACT DAB Peroxidase  VectorLabs, SK-4105 
ExtraAvidin®    Sigma-Aldrich, E2886  
Cytation 5 (Gen 5 Image+ 2.09) Biotek (Millennium Science) 
ImageJ 2.0.0    FIJI 




Appendix B: Soultions and Buffers 
 
PB 
0.1M PB  
Solution A - 27.6 g sodium phosphate monobasic (NaH2PO4H2O) in 1 L dH2O  
Solution B - 53.56 g sodium phosphate dibasic (Na2HPO47H2O) in 1 L dH2O  
Mix 280 mL of solution A with 720 mL of solution B  
Dilute with dH2O to a volume of 2 L 
4% Paraformaldehyde  
40 g paraformaldehyde (PFA)  
 500 mL 0.1 M PB  
 Stir and warm to 60°C until the PFA has dissolved  
Fill to 1 L with 0.1 M PB  
Filter and pH to 7.4  
Cryoprotectant  
400 mL 0.1M PB  
300 g Sucrose  
300 mL Ethylene glycol  
Anitfade  
20 mL of 0.1M PB  





1 L 0.1M PB  
126.9 g of sodium chloride (NaCl)  
PBS-T (0.2% Triton) 
500 mL of 1x PBS  
1 mL of Triton X-100   
	
106 
Appendix C: Drug Information 
 












Appendix D: Example Drug Dosage Calculations 
 
High Dose – 25 mg/kg  
Example mouse weight – 25.0 g 
   25  / 1000 = 0.025 
Mouse weight in kg 
   0.025 x 25 = 0.625  
Daily dose of CBD in mg and jelly volume in mL 
   0.625 x 7 = 4.375  
Weekly dose CBD in mg and volume jelly in mL 
   (50 / 1.5)  / 4.375 = 0.131 
Total volume of vehicle in mL 
  0.131 / 3 = 0.0438 
Volume each vehicle component in mL 
   0.0438 x 1000 = 43.75 
Volume of each vehicle component in μL 
 
For a week worth of jelly, 4.375 mg of CBD is dissolved in 43.75 μL of olive oil then 
added to 43.75 μL of ethanol and 43.75 μL of TWEEN® 20. This solution is then 
added to 4.375 mL of cooled jelly solution. This solution is then pipetted into 24-well 
plates with 2-days worth of jelly in each well – i.e. 1.25 mL per well, with 0.625 in 
the last well for the 7th day.  
 
Low Dose – 10 mg/kg  
Example mouse weight – 25.0 g 
   25  / 1000 = 0.025 
Mouse weight in kg 
   0.025 x 25 = 0.625  
Daily volume in mL 
   0.025 x 10 = 0.25 
Daily dose of CBD in mg 
   0.25  x 7 = 1.75 
Weekly dose of CBD in mg 
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   0.625 x 7 = 4.375  
Weekly volume jelly in mL 
   (50 / 1.5)  / 4.375 = 0.131 
Total volume of vehicle in mL 
  0.131 / 3 = 0.0438 
Volume each vehicle component in mL 
   0.0438 x 1000 = 43.75 
Volume of each vehicle component in μL 
 
For a week’s worth of jelly, 41.75 mg of CBD is dissolved in 43.75 μL of olive oil 
then added to 43.75 μL of ethanol and 43.75 μL of TWEEN® 20. This solution is 
then added to 4.375 mL of cooled jelly solution. This solution is then pipetted into 24-
well plates with 2-days worth of jelly in each well – i.e. 1.25 mL per well, with 0.625 





Appendix E: Cytation, Photoshop® and ImageJ Functions 
 
Immunolabelled Imaging (Cytation) 
Bright Field 
LED     5  
Integration Time    100 
Gain     0 
 
Autofluorescence Imaging (Cytation) 
GFP 469, 525 
LED     1 
Integration Time    600 
Gain     24 
 
Image Merging (Photoshop®) 
File  > Automate  > Photomerge  
Select images 
Select ‘Reposition’  
Flatten Image 
 
Cell Counting – Percentage Area (ImageJ) 
Image  > Type > 8-bit 
Edit   > Invert 
Image   > Adjust   >  Threshold 
Analyze > Analyze Particles  
 ‘Analyze Particles’ settings varied between section preparations 
 
Cell Counting – Stereology (ImageJ) 
Select area of interest > Ctrl + M 
Analyze  >  Tools  >  Grid (Plugin) >  
Grid type  Lines 
Area per point 10,000 
Select ‘Random offset’ 
